<html lang="en" class="pb-page js" data-request-id="94d665ab0632a444-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d665ab0632a444-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/QmIJhOwQUCd0Z_5Z7pslaDbElT7vEhojn_XqoxWU8BVd36jPdYKRh6R3JbSFCpsKoRmbSReUD6J--2mkeT9Mng=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Bupropion and Naltrexone in Methamphetamine Use Disorder | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d665ab0632a444-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.08910180192139372"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="Specialties" content="Psychiatry|Neurology/Neurosurgery">
<meta name="articleType" content="Original Article">
<meta name="articleCategory" content="Research">
<meta name="topics" content="Addiction|Neurology/Neurosurgery General"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2020214","title":"Bupropion and Naltrexone in Methamphetamine Use Disorder","category":"Research","type":"Original Article","topics":"Addiction|Neurology/Neurosurgery General","specialties":"Psychiatry|Neurology/Neurosurgery","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2021-01-14T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"Specialties\" content\u003d\"Psychiatry|Neurology/Neurosurgery\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Addiction|Neurology/Neurosurgery General\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2020214","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d665ab0632a444-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Bupropion and Naltrexone in Methamphetamine Use Disorder"><meta name="dc.Creator" content="Madhukar H. Trivedi"><meta name="dc.Creator" content="Robrina Walker"><meta name="dc.Creator" content="Walter Ling"><meta name="dc.Creator" content="Adriane dela Cruz"><meta name="dc.Creator" content="Gaurav Sharma"><meta name="dc.Creator" content="Thomas Carmody"><meta name="dc.Creator" content="Udi E. Ghitza"><meta name="dc.Creator" content="Aimee Wahle"><meta name="dc.Creator" content="Mora Kim"><meta name="dc.Creator" content="Kathy Shores-Wilson"><meta name="dc.Creator" content="Steven Sparenborg"><meta name="dc.Creator" content="Phillip Coffin"><meta name="dc.Creator" content="Joy Schmitz"><meta name="dc.Creator" content="Katharina Wiest"><meta name="dc.Creator" content="Gavin Bart"><meta name="dc.Creator" content="Susan C. Sonne"><meta name="dc.Creator" content="Sidarth Wakhlu"><meta name="dc.Creator" content="A. John Rush"><meta name="dc.Creator" content="Edward V. Nunes"><meta name="dc.Creator" content="Steven Shoptaw"><meta name="dc.Description" content="The use of naltrexone plus bupropion to treat methamphetamine use disorder has not been well studied.We conducted this multisite, double-blind, two-stage, placebo-controlled trial with the use of a..."><meta name="Description" content="The use of naltrexone plus bupropion to treat methamphetamine use disorder has not been well studied.We conducted this multisite, double-blind, two-stage, placebo-controlled trial with the use of a..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2021-01-14"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2020214"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202101143840209"><meta name="dc.Language" content="EN"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2021 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2020214">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2020214">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2020214">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Bupropion and Naltrexone in Methamphetamine Use Disorder | NEJM">
        <meta property="og:title" content="Bupropion and Naltrexone in Methamphetamine Use Disorder | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2020214">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/29a29702-674e-4ad1-b557-0e0c4d7ccae7/nejmoa2020214_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/29a29702-674e-4ad1-b557-0e0c4d7ccae7/nejmoa2020214_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="The use of naltrexone plus bupropion to treat methamphetamine use disorder has not
been well studied. We conducted this multisite, double-blind, two-stage, placebo-controlled
trial with the use of ...">
        <meta name="twitter:description" content="The use of naltrexone plus bupropion to treat methamphetamine use disorder has not
been well studied. We conducted this multisite, double-blind, two-stage, placebo-controlled
trial with the use of ...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="3213">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa2020214">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2020214">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:MMS NextGen Website Group;issue:issue:doi\:10.1056/nejm_2021.384.issue-2;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms;article:article:doi\:10.1056/NEJMoa2020214">
        <link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2020214" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2020214" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2020214" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2020214" class="inputDoi"><input type="hidden" value="M.H. Trivedi and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2021;384:140-153" class="inputCitation"><input type="hidden" value="01-13-2021" class="inputEPubDate"><input type="hidden" value="January 2021" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Bupropion and Naltrexone in Methamphetamine Use Disorder" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d665ab0632a444-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Bupropion and Naltrexone in Methamphetamine Use Disorder</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Madhukar H.</span> <span property="familyName">Trivedi</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Robrina</span> <span property="familyName">Walker</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Walter</span> <span property="familyName">Ling</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Adriane</span> <span property="familyName">dela Cruz</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Gaurav</span> <span property="familyName">Sharma</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Thomas</span> <span property="familyName">Carmody</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Udi E.</span> <span property="familyName">Ghitza</span>, <span property="honorificSuffix">Ph.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+12</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Aimee</span> <span property="familyName">Wahle</span>, <span property="honorificSuffix">M.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Mora</span> <span property="familyName">Kim</span>, <span property="honorificSuffix">M.P.H.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Kathy</span> <span property="familyName">Shores-Wilson</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Steven</span> <span property="familyName">Sparenborg</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Phillip</span> <span property="familyName">Coffin</span>, <span property="honorificSuffix">M.D., M.I.A.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Joy</span> <span property="familyName">Schmitz</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Katharina</span> <span property="familyName">Wiest</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Gavin</span> <span property="familyName">Bart</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Susan C.</span> <span property="familyName">Sonne</span>, <span property="honorificSuffix">Pharm.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sidarth</span> <span property="familyName">Wakhlu</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">A. John</span> <span property="familyName">Rush</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Edward V.</span> <span property="familyName">Nunes</span>, <span property="honorificSuffix">M.D.</span></span></span>, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Steven</span> <span property="familyName">Shoptaw</span>, <span property="honorificSuffix">Ph.D.</span></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-12</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">January 13, 2021</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2021<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">384</span></span>:<span property="pageStart">140</span>-<span property="pageEnd">153</span></div><div class="doi">DOI: 10.1056/NEJMoa2020214</div><div class="core-enumeration"><a href="/toc/nejm/384/2"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">384</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">2</span></span></a></div><div><a href="#tab-information">Copyright © 2021</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DMadhukar%2BH.%2BTrivedi%252C%2BRobrina%2BWalker%252C%2BWalter%2BLing%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D384%26issueNum%3D2%26contentID%3D10.1056%252FNEJMoa2020214%26title%3DBupropion%2Band%2BNaltrexone%2Bin%2BMethamphetamine%2BUse%2BDisorder%26publicationDate%3D01%252F14%252F2021" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2020214" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DMadhukar%2BH.%2BTrivedi%252C%2BRobrina%2BWalker%252C%2BWalter%2BLing%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D384%26issueNum%3D2%26contentID%3D10.1056%252FNEJMoa2020214%26title%3DBupropion%2Band%2BNaltrexone%2Bin%2BMethamphetamine%2BUse%2BDisorder%26publicationDate%3D01%252F14%252F2021" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/06eaa24e-b5ca-4f2f-90ab-52efa1fa2c9e/nejmoa2020214.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2020214.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2020214" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2020214" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2020214.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">The use of naltrexone plus bupropion to treat methamphetamine use disorder has not been well studied.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">We conducted this multisite, double-blind, two-stage, placebo-controlled trial with the use of a sequential parallel comparison design to evaluate the efficacy and safety of extended-release injectable naltrexone (380 mg every 3 weeks) plus oral extended-release bupropion (450 mg per day) in adults with moderate or severe methamphetamine use disorder. In the first stage of the trial, participants were randomly assigned in a 0.26:0.74 ratio to receive naltrexone–bupropion or matching injectable and oral placebo for 6 weeks. Those in the placebo group who did not have a response in stage 1 underwent rerandomization in stage 2 and were assigned in a 1:1 ratio to receive naltrexone–bupropion or placebo for an additional 6 weeks. Urine samples were obtained from participants twice weekly. The primary outcome was a response, defined as at least three methamphetamine-negative urine samples out of four samples obtained at the end of stage 1 or stage 2, and the weighted average of the responses in the two stages is reported. The treatment effect was defined as the between-group difference in the overall weighted responses.</div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">A total of 403 participants were enrolled in stage 1, and 225 in stage 2. In the first stage, 18 of 109 participants (16.5%) in the naltrexone–bupropion group and 10 of 294 (3.4%) in the placebo group had a response. In the second stage, 13 of 114 (11.4%) in the naltrexone–bupropion group and 2 of 111 (1.8%) in the placebo group had a response. The weighted average response across the two stages was 13.6% with naltrexone–bupropion and 2.5% with placebo, for an overall treatment effect of 11.1 percentage points (Wald z-test statistic, 4.53; P&lt;0.001). Adverse events with naltrexone–bupropion included gastrointestinal disorders, tremor, malaise, hyperhidrosis, and anorexia. Serious adverse events occurred in 8 of 223 participants (3.6%) who received naltrexone–bupropion during the trial.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">Among adults with methamphetamine use disorder, the response over a period of 12 weeks among participants who received extended-release injectable naltrexone plus oral extended-release bupropion was low but was higher than that among participants who received placebo. (Funded by the National Institute on Drug Abuse and others; ADAPT-2 ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT03078075" target="_blank">NCT03078075</a>.)</div></section></section></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">There has been a rise in methamphetamine use disorder in the United States, particularly in the Midwest and West, where methamphetamine is a leading cause of overdose deaths.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2" id="body-ref-r2" href-manipulated="true">1,2</a></sup> There is no medication approved by the Food and Drug Administration for the treatment of methamphetamine use disorder, and effective treatment has been identified as an essential public health goal.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r4" id="body-ref-r4" href-manipulated="true">3,4</a></sup></div><div role="paragraph">Bupropion<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5 r6 r7" id="body-ref-r7" href-manipulated="true">5-7</a></sup> and naltrexone<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8 r9 r10" id="body-ref-r10-1" href-manipulated="true">8-10</a></sup> used individually have shown some positive evidence of efficacy in clinical trials for the treatment of methamphetamine use disorder.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11 r12 r13" id="body-ref-r13" href-manipulated="true">11-13</a></sup> Bupropion is a stimulant-like antidepressant that acts through the norepinephrine and dopamine systems and might ameliorate the dysphoria associated with methamphetamine withdrawal that drives continued use.<sup><a href="#core-r14" role="doc-biblioref" data-xml-rid="r14 r15" id="body-ref-r15" href-manipulated="true">14,15</a></sup> Naltrexone is an opioid-receptor antagonist that is effective for the treatment of opioid use disorder. In some trials, it has also been shown to have a modest effect in preventing relapse of alcohol use,<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16" id="body-ref-r16" href-manipulated="true" aria-label="Reference 16">16</a></sup> perhaps by attenuating the reinforcing effects of substances or cue-induced cravings.<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10 r17 r18" id="body-ref-r18" href-manipulated="true">10,17,18</a></sup> The results of a small, open-label pilot trial suggested that naltrexone plus bupropion might be effective for the treatment of severe methamphetamine use disorder.<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19" id="body-ref-r19-1" href-manipulated="true" aria-label="Reference 19">19</a></sup> These findings supported the development of the current trial (Accelerated Development of Additive Treatment for Methamphetamine Disorder [ADAPT-2]), which assessed the efficacy of combining these agents for the treatment of methamphetamine use disorder.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Trial Design and Conduct</h3><div role="paragraph">This randomized, double-blind trial, which used a sequential parallel comparison design,<sup><a href="#core-r20" role="doc-biblioref" data-xml-rid="r20 r21" id="body-ref-r21-1" href-manipulated="true">20,21</a></sup> was conducted at eight sites from May 23, 2017, to July 25, 2019. It evaluated the efficacy and safety of extended-release injectable naltrexone (380 mg every 3 weeks) combined with once-daily oral extended-release bupropion (450 mg per day) as compared with placebo in adult outpatients with moderate or severe methamphetamine use disorder.</div><div role="paragraph">This 12-week trial was conducted in two stages consisting of 6 weeks each. Participants initially underwent randomization in a 0.26:0.74 ratio to receive naltrexone–bupropion or placebo during the first 6-week stage; participants in the placebo group who did not have a response in the first stage underwent randomization again in a 1:1 ratio in the second 6-week stage (<a href="#f1">Figure 1</a>). The ratios used for randomization were chosen on the basis of established practices in sequential parallel design trials and are described in the Statistical Analysis section and in the statistical analysis plan, included in the <a href="#ap1">protocol</a> (available with the full text of this article at NEJM.org).<sup><a href="#core-r22" role="doc-biblioref" data-xml-rid="r22" id="body-ref-r22-1" href-manipulated="true" aria-label="Reference 22">22</a></sup> The purpose of rerandomization was to enrich the sample in the second stage with participants who were unlikely to have a response to placebo. The results from both stages were combined for analysis as described in the statistical analysis plan.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2020214_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2020214_f1.jpg"><img src="/cms/10.1056/NEJMoa2020214/asset/29a29702-674e-4ad1-b557-0e0c4d7ccae7/assets/images/large/nejmoa2020214_f1.jpg" height="3213" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Screening and Randomization.</div><div class="notes"><div role="doc-footnote">Participants may have had more than one reason for not undergoing randomization in stage 1. The analysis of the primary outcome was performed in the intention-to-treat population, which included all participants who underwent randomization in stage 1 and all participants who underwent randomization again in stage 2.</div></div></figcaption></figure></div><div role="paragraph">Participants visited the clinic twice a week for drug screening of urine samples (for a potential total of 24 urine samples per participant [12 in each stage]), for safety monitoring, and for assessments. Additional safety and outcome assessments were performed at week 6 and week 12. The integrity of urine samples was determined with the use of an embedded temperature strip on the collection cup (valid samples were considered to be those with a temperature of 32° to 38°C [90° to 100°F]) and a negative test for adulterants. Valid samples were tested for 10 drugs with the use of a point-of-care urine drug test card in accordance with the regulations of the Clinical Laboratory Improvement Amendments of 1988.</div><div role="paragraph">Extended-release naltrexone was supplied in standard single-use intramuscular injection kits, each containing one 380-mg vial of naltrexone microspheres. In each stage, injections of naltrexone or placebo were administered by trial clinicians on the day of randomization (or rerandomization) and in the third week of each stage. Naltrexone was administered every 3 weeks to mitigate the lower naltrexone blood levels that would most likely occur with a 4-week injection schedule, according to the product labeling.</div><div role="paragraph">Extended-release bupropion (in 150-mg tablets) or placebo was provided weekly in matching blister cards. Beginning on the day of randomization or rerandomization, the dose was raised over the course of 3 days to a total daily dose of 450 mg. If appropriate, doses could be reduced before week 13 to 300 mg per day to alleviate adverse effects; clinicians were encouraged to attempt to raise the dose back up to the target dose. At the end of the trial (week 13), the dose was tapered over a period of 4 days, at which point it was discontinued.</div><div role="paragraph">Adherence to the assigned regimen was determined by participant-reported tablet ingestion (confirmed on the basis of tablet count) and by documentation by the trial staff who administered the injections. To encourage adherence, participants were asked to use a smartphone-based application to track tablet ingestion. Trial clinicians, who were unaware of group assignments, met weekly with participants to manage adverse events, assess and encourage adherence to the oral regimen, address participant concerns, and provide counseling for reducing substance use.</div></section><section id="sec-1-2"><h3>Trial Oversight</h3><div role="paragraph">The trial was conducted in accordance with the principles of the Declaration of Helsinki. The protocol was approved by the data and safety monitoring board of the National Institute on Drug Abuse (NIDA) Clinical Trials Network, by a central institutional review board, and by institutional review boards at four sites. The data and safety monitoring board monitored trial progress and safety, reviewed a one-time sample-size reestimation and interim efficacy analysis, and appraised the final outcome and safety results. The data analysis was performed by the fifth, sixth, and eighth authors. The first draft of the manuscript was written by the second author. All authors vouch for the adherence of the trial to the protocol, the completeness and accuracy of the data, and the complete reporting of adverse events. Alkermes donated naltrexone in the form of extended-release injectable suspension and matched injectable placebo for this trial under a written agreement with NIDA (the sponsor). AiCure (New York) provided the smartphone-based application for tracking adherence to the oral regimen under a paid subcontract. Neither company had a role in the collection or analysis of the data or the writing of the manuscript. There were no confidentiality agreements between the investigators and the commercial entities.</div></section><section id="sec-1-3"><h3>Participants</h3><div role="paragraph">Adults 18 to 65 years of age who wanted to quit or reduce methamphetamine use were recruited from communities near the trial sites with the use of advertisements (e.g., print, Web, radio, and television advertising) and through direct referrals (e.g., by participants who were already enrolled in the trial, medical clinics, and social-service agencies). Eligible participants met the criteria of the <i>Diagnostic and Statistical Manual of Mental Disorders</i>, fifth edition (DSM-5), for moderate or severe stimulant use disorder (methamphetamine type); reported methamphetamine use on at least 18 of the 30 days before consent; had two or more methamphetamine-positive urine samples (obtained ≥2 days apart) within 10 days before randomization; and were opioid-free at the time of randomization. Participants were excluded if they were undergoing concurrent treatment for substance use disorder, had an expected need for opioid-containing medications (e.g., planned surgery) during the trial, or did not meet additional criteria that would ensure that participation would be safe (e.g., participants would not be eligible if they had conditions that increased the risk of seizure or were taking medications that were contraindicated). Participants who had received a diagnosis of a specific medical or psychiatric disorder were not routinely excluded and were evaluated on a case-by-case basis to determine whether it was safe for them to participate.</div><div role="paragraph">Persons who were interested in participation completed a brief telephone prescreening, and, if appropriate, a visit was scheduled so that participants could learn about trial procedures and the potential benefits and risks of participation, have the opportunity to ask questions, and provide written informed consent. After consent was obtained, a screening period of 4 to 21 days was begun to evaluate eligibility criteria. Eligible participants were then randomly assigned to receive naltrexone–bupropion or placebo. Participants were compensated for participation in the trial. Details on eligibility criteria and compensation are provided in the protocol.</div></section><section id="sec-1-4"><h3>Outcomes</h3><div role="paragraph">The primary outcome was a response to the trial regimen, defined as at least three methamphetamine-negative urine tests out of a possible four obtained at the end of stage 1 (during week 5 through week 6) or at the end of stage 2 (during week 11 through week 12). A response was included in the analysis only in the stage in which it first occurred. Participants who had two or more missing results of urine drug screenings or who discontinued the trial were recorded as not having had a response. To combine results across the two trial stages, the weighted average of the responses across the two stages was calculated for each trial group. The overall treatment effect was defined as the between-group difference in the weighted responses.</div><div role="paragraph">Secondary outcomes that were evaluated in each stage were the percentage of methamphetamine-negative urine samples (i.e., the number of methamphetamine-negative urine samples per stage divided by 12, which was the total number of samples expected in each stage); the most severe methamphetamine craving during the previous week,<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23" id="body-ref-r23" href-manipulated="true" aria-label="Reference 23">23</a></sup> assessed weekly with the use of a visual analogue scale (values range from 0 to 100, with higher values indicating greater cravings); depressive symptoms, assessed weekly with the use of the Patient Health Questionnaire 9 (PHQ-9; each of nine items is given a score of 0 to 3, with a score of 0 indicating the absence of depressive symptoms and a score of 3 indicating the presence of depressive symptoms nearly every day; total scores range from 0 to 27, with higher scores indicating greater depressive symptoms); and results of the Treatment Effectiveness Assessment at week 6 and week 12, which assesses reduced substance use and improvements in lifestyle, health, and community and interpersonal interactions according to participant report<sup><a href="#core-r24" role="doc-biblioref" data-xml-rid="r24 r25" id="body-ref-r25" href-manipulated="true">24,25</a></sup> (total scores range from 4 to 40, with higher scores indicating greater improvement in these factors).</div><div role="paragraph">Safety outcomes were assessed at each visit and included participant-reported adverse events and assessment of vital signs, liver-function tests, injection-site reactions, results on electrocardiograms, and suicidality.<sup><a href="#core-r26" role="doc-biblioref" data-xml-rid="r26" id="body-ref-r26" href-manipulated="true" aria-label="Reference 26">26</a></sup> Adverse events were classified according to the preferred term and system organ class of the <i>Medical Dictionary for Regulatory Activities</i>, version 22.1. Site investigators, who were unaware of trial-group assignments, determined whether an event was a serious adverse event and evaluated the severity and cause of the event. Serious adverse events were adjudicated by a medical monitor assigned by the sponsor.</div></section><section id="sec-1-5"><h3>Statistical Analysis</h3><div role="paragraph">According to the sample-size calculation,<sup><a href="#core-r22" role="doc-biblioref" data-xml-rid="r22" id="body-ref-r22-2" href-manipulated="true" aria-label="Reference 22">22</a></sup> we determined that 370 participants would give the trial 90% power to detect a weighted difference between the two trial groups under the assumption that 24% of participants in the naltrexone–bupropion group and 15% in the placebo group would have a response in stage 1, and 24% in the naltrexone–bupropion group and 10% in the placebo group would have a response in stage 2. The assumption that 24% of participants in the naltrexone–bupropion group would have a response was determined on the basis of a small pilot study.<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19" id="body-ref-r19-2" href-manipulated="true" aria-label="Reference 19">19</a></sup> Because the goal of stage 2 was to enrich the sample by including only participants in the placebo group who did not have a response in stage 1, we expected a smaller number of participants in the placebo group to have a response in stage 2 than in stage 1. The prespecified sample-size reestimation analysis was performed with data from the first 185 participants who underwent randomization. Investigators were not informed of the results of the reestimation analysis. The data and safety monitoring board recommended increasing the sample size to 400 to maintain 90% power to detect a difference in response between the two groups. This recommendation was approved by the sponsor on August 13, 2018.</div><div role="paragraph">The trial used a two-stage, sequential parallel comparison design.<sup><a href="#core-r20" role="doc-biblioref" data-xml-rid="r20 r21" id="body-ref-r21-2" href-manipulated="true">20,21</a></sup> This design requires two parameters: a randomization fraction and a weight. Each value was chosen to maximize the power of the test in accordance with the sample-size calculation, resulting in a randomization ratio in stage 1 of 0.26:0.74 to naltrexone–bupropion or placebo. The overall treatment effect with this design was defined as the average response in the naltrexone–bupropion group minus the average response in the placebo group, calculated with the use of a weight of 0.43 in stage 1 and a weight of 0.57 in stage 2. Additional information regarding the formula used to calculate the size of the treatment effect, h=[w(p1)+(1−w)p2]−[w(q1)+(1−w)(q2)] (with h indicating the overall treatment effect, w indicating the weight, p1 indicating the response in the naltrexone–bupropion group in stage 1, p2 indicating the response in the naltrexone–bupropion group in stage 2, q1 indicating the response in the placebo group in stage 1, and q2 indicating the response in the placebo group in stage 2), is provided in the statistical analysis plan.</div><div role="paragraph">The analyses were performed in the intention-to-treat population, which included all participants who underwent randomization in stage 1 and all participants who underwent randomization again in stage 2 (Fig. S1 in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org). The primary outcome was evaluated with the use of a one-sided Wald z-test statistic<sup><a href="#core-r22" role="doc-biblioref" data-xml-rid="r22" id="body-ref-r22-3" href-manipulated="true" aria-label="Reference 22">22</a></sup> with a one-sided type I error rate of 0.025, corresponding to a two-sided test with an alpha level of 0.05. The standard error of h accounted for the inclusion of some participants from stage 1 in stage 2. To determine the sensitivity of these results, we repeated the primary outcome analysis with the use of a prespecified complete-case approach (a complete case was defined as four urine samples obtained during the final 2 weeks of each stage). We conducted an additional prespecified sensitivity analysis that assumed equal weight for each stage. Subgroup effects according to trial site, sex, race, ethnic group, and age were assessed with the use of generalized linear mixed models and a forest plot presenting the treatment effect with 95% confidence intervals.</div><div role="paragraph">Secondary outcomes were analyzed with the use of the Doros method<sup><a href="#core-r27" role="doc-biblioref" data-xml-rid="r27" id="body-ref-r27" href-manipulated="true" aria-label="Reference 27">27</a></sup> for repeated measures of a continuous outcome. Because there was no prespecified plan for adjustment of confidence intervals for multiple comparisons of secondary outcomes, no clinical conclusions can be drawn from these results. Adverse events were compared between groups in stage 1 and stage 2 with Fisher’s exact tests. All analyses were conducted with SAS software, version 9.4 (SAS Institute).</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Participants</h3><div role="paragraph">A total of 403 participants underwent randomization in stage 1: 109 participants (27.0%) were assigned to receive naltrexone–bupropion, and 294 (73.0%) to receive placebo (<a href="#f1">Figure 1</a>). Of the 225 participants in the placebo group who did not have a response in stage 1 and underwent randomization again in stage 2, a total of 114 (50.7%) were assigned to receive naltrexone–bupropion and 111 (49.3%) to receive placebo. The 403 participants who underwent randomization in stage 1 were assessed for the primary outcome at the end of the trial. <a href="#t1">Table 1</a> shows demographic and clinical characteristics of all participants according to group assignment. The average age of participants was 41 years, 68.7% were male, 71.2% were White, and 38.7% were employed. On average, participants used methamphetamine on 27 of the 30 days before consent was provided.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2020214_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2020214_t1.jpg"><img src="/cms/10.1056/NEJMoa2020214/asset/6a2a379b-f205-464b-8682-a7459b4d9d80/assets/images/large/nejmoa2020214_t1.jpg" height="3001" width="2615" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">All Participants</th><th class="txxx-borders" colspan="2"><span>Stage 1</span></th><th class="txxr-borders" colspan="2"><span>Stage 2</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Total<a href="#t1fn2" role="doc-noteref">†</a><br>(N=403)</th><th class="xxxx-borders">Naltrexone–Bupropion<br>(N=109)</th><th class="xxxx-borders">Placebo<br>(N=294)</th><th class="xxxx-borders">Naltrexone–Bupropion<br>(N=114)</th><th class="xxxr-borders">Placebo<br>(N=111)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Demographic characteristics</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Male — no. (%)</td><td class="xxxx-borders">277 (68.7)</td><td class="xxxx-borders">78 (71.6)</td><td class="xxxx-borders">199 (67.7)</td><td class="xxxx-borders">78 (68.4)</td><td class="xxxr-borders">79 (71.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Age — yr</td><td class="xxxx-borders shading">41.0±10.1</td><td class="xxxx-borders shading">41.0±10.6</td><td class="xxxx-borders shading">41.0±10.0</td><td class="xxxx-borders shading">41.0±10.5</td><td class="xxxr-borders shading">42.0±9.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Hispanic or Latino ethnic group — no. (%)<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">55 (13.6)</td><td class="xxxx-borders">13 (11.9)</td><td class="xxxx-borders">42 (14.3)</td><td class="xxxx-borders">20 (17.5)</td><td class="xxxr-borders">18 (16.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Race or ethnic group — no. (%)<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">White</td><td class="xxxx-borders">287 (71.2)</td><td class="xxxx-borders">82 (75.2)</td><td class="xxxx-borders">205 (69.7)</td><td class="xxxx-borders">84 (73.7)</td><td class="xxxr-borders">69 (62.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Black</td><td class="xxxx-borders shading">48 (11.9)</td><td class="xxxx-borders shading">10 (9.2)</td><td class="xxxx-borders shading">38 (12.9)</td><td class="xxxx-borders shading">8 (7.0)</td><td class="xxxr-borders shading">22 (19.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Other</td><td class="xxxx-borders">68 (16.9)</td><td class="xxxx-borders">17 (15.6)</td><td class="xxxx-borders">51 (17.3)</td><td class="xxxx-borders">22 (19.3)</td><td class="xxxr-borders">20 (18.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">High school diploma, GED, or lower education level — no. (%)</td><td class="xxxx-borders shading">142 (35.2)</td><td class="xxxx-borders shading">39 (35.8)</td><td class="xxxx-borders shading">103 (35.0)</td><td class="xxxx-borders shading">36 (31.6)</td><td class="xxxr-borders shading">33 (29.7)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Marital status — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Married or living with partner</td><td class="xxxx-borders shading">93 (23.1)</td><td class="xxxx-borders shading">26 (23.9)</td><td class="xxxx-borders shading">67 (22.8)</td><td class="xxxx-borders shading">25 (21.9)</td><td class="xxxr-borders shading">25 (22.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Never married</td><td class="xxxx-borders">204 (50.6)</td><td class="xxxx-borders">49 (45.0)</td><td class="xxxx-borders">155 (52.7)</td><td class="xxxx-borders">60 (52.6)</td><td class="xxxr-borders">59 (53.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Divorced, separated, widowed, or unknown — no. (%)</td><td class="xxxx-borders shading">106 (26.3)</td><td class="xxxx-borders shading">34 (31.2)</td><td class="xxxx-borders shading">72 (24.5)</td><td class="xxxx-borders shading">29 (25.4)</td><td class="xxxr-borders shading">27 (24.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Employed — no. (%)<a href="#t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">156 (38.7)</td><td class="xxxx-borders">43 (39.4)</td><td class="xxxx-borders">113 (38.4)</td><td class="xxxx-borders">46 (40.4)</td><td class="xxxr-borders">44 (39.6)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Methamphetamine use</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">No. of days that methamphetamine was used in the 30 days before consent<a href="#t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">26.7±4.1</td><td class="xxxx-borders">27.0±3.9</td><td class="xxxx-borders">26.5±4.2</td><td class="xxxx-borders">26.7±4.1</td><td class="xxxr-borders">26.1±4.3</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Most frequent route of methamphetamine use — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Smoking</td><td class="xxxx-borders">293 (72.7)</td><td class="xxxx-borders">80 (73.4)</td><td class="xxxx-borders">213 (72.4)</td><td class="xxxx-borders">83 (72.8)</td><td class="xxxr-borders">79 (71.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Intravenous</td><td class="xxxx-borders shading">77 (19.1)</td><td class="xxxx-borders shading">23 (21.1)</td><td class="xxxx-borders shading">54 (18.4)</td><td class="xxxx-borders shading">21 (18.4)</td><td class="xxxr-borders shading">22 (19.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Nasal or oral</td><td class="xxxx-borders">33 (8.2)</td><td class="xxxx-borders">6 (5.5)</td><td class="xxxx-borders">27 (9.2)</td><td class="xxxx-borders">10 (8.8)</td><td class="xxxr-borders">10 (9.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Participants reporting intravenous methamphetamine use ≥1 days in the 30 days before consent — no. (%)</td><td class="xxxx-borders shading">135 (33.5)</td><td class="xxxx-borders shading">39 (35.8)</td><td class="xxxx-borders shading">96 (32.7)</td><td class="xxxx-borders shading">38 (33.3)</td><td class="xxxr-borders shading">36 (32.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Intensity of methamphetamine craving<a href="#t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">66.1±22.3</td><td class="xxxx-borders">65.7±22.2</td><td class="xxxx-borders">65.8±21.6</td><td class="xxxx-borders">66.7±21.3</td><td class="xxxr-borders">63.7±21.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Age of first methamphetamine use — yr</td><td class="xxxx-borders shading">24.8±9.9</td><td class="xxxx-borders shading">24.7±10.7</td><td class="xxxx-borders shading">24.8±9.6</td><td class="xxxx-borders shading">25.5±10.9</td><td class="xxxr-borders shading">24.8±9.1</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Other characteristics</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Coexisting cocaine use disorder according to DSM-5 criteria — no./total no. (%)</td><td class="xxxx-borders shading">31/365 (8.5)</td><td class="xxxx-borders shading">9/97 (9.3)</td><td class="xxxx-borders shading">22/268 (8.2)</td><td class="xxxx-borders shading">9/104 (8.7)</td><td class="xxxr-borders shading">9/100 (9.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Coexisting opioid use disorder according to DSM-5 criteria — no./total no. (%)</td><td class="xxxx-borders">27/370 (7.3)</td><td class="xxxx-borders">7/93 (7.5)</td><td class="xxxx-borders">20/277 (7.2)</td><td class="xxxx-borders">7/109 (6.4)</td><td class="xxxr-borders">7/104 (6.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Coexisting alcohol use disorder according to DSM-5 criteria — no./total no. (%)</td><td class="xxxx-borders shading">94/293 (32.1)</td><td class="xxxx-borders shading">25/77 (32.5)</td><td class="xxxx-borders shading">69/216 (31.9)</td><td class="xxxx-borders shading">23/85 (27.1)</td><td class="xxxr-borders shading">27/75 (36.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Coexisting cannabis use disorder according to DSM-5 criteria — no./total no. (%)</td><td class="xxxx-borders">116/318 (36.5)</td><td class="xxxx-borders">29/89 (32.6)</td><td class="xxxx-borders">87/229 (38.0)</td><td class="xxxx-borders">33/86 (38.4)</td><td class="xxxr-borders">33/85 (38.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Daily nicotine cigarette use — no./total no. (%)</td><td class="xxxx-borders shading">238/337 (70.6)</td><td class="xxxx-borders shading">66/99 (66.7)</td><td class="xxxx-borders shading">172/238 (72.3)</td><td class="xxxx-borders shading">73/89 (82.0)</td><td class="xxxr-borders shading">56/89 (62.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Score on PHQ-9 depression scale<a href="#t1fn7" role="doc-noteref">**</a></td><td class="xxxx-borders">19.9±6.5</td><td class="xxxx-borders">19.4±6.5</td><td class="xxxx-borders">20.0±6.5</td><td class="xxxx-borders">20.1±6.9</td><td class="xxxr-borders">19.5±5.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Score on Treatment Effectiveness Assessment<a href="#t1fn8" role="doc-noteref">††</a></td><td class="xxxx-borders shading">18.3±7.2</td><td class="xxxx-borders shading">16.7±7.0</td><td class="xxxx-borders shading">18.6±7.3</td><td class="xxxx-borders shading">18.4±7.5</td><td class="xxxr-borders shading">19.2±7.1</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02" data-xml-align="left">HIV-positive status — no./total no. (%)</td><td class="xbxx-borders">90/356 (25.3)</td><td class="xbxx-borders">24/92 (26.1)</td><td class="xbxx-borders">66/264 (25.0)</td><td class="xbxx-borders">24/96 (25.0)</td><td class="xbxr-borders">33/105 (31.4)</td></tr></tbody></table></div><figcaption><div class="caption">Baseline Characteristics of the Participants in the Intention-to-Treat Population.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Plus–minus values are means ±SD. The intention-to-treat population included all participants who underwent randomization in stage 1 and the participants who underwent randomization again in stage 2. DSM-5 denotes <i>Diagnostic and Statistical Manual of Mental Disorders</i>, fifth edition, and GED General Educational Development diploma. Percentages may not total 100 because of rounding.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">The total number reflects all participants who underwent randomization in stage 1.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">Race and ethnic group were reported by the participants. The “other” category included American Indian or Alaska Native (6 participants), Asian (11 participants), Native Hawaiian or Pacific Islander (2 participants), other (20 participants), multiracial (16 participants), don’t know (10 participants), and declined to answer (3 participants).</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t1fn4" role="paragraph">The remaining participants were unemployed, disabled, or retired; were keeping house; were students; or had other status.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t1fn5" role="paragraph">The number of days of methamphetamine use at baseline was assessed for the 30 days before informed consent. One participant had only 24 days of assessment. Eligibility required a minimum of 18 days of methamphetamine use at baseline.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t1fn6" role="paragraph">Methamphetamine craving (the intensity of the worst craving over the previous week) was assessed at each screening or baseline visit on a visual analogue scale; ratings on the scale, which range from 0 to 100, were averaged to determine a baseline craving, with 0 indicating no craving at all and 100 indicating the most intense craving possible.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="t1fn7" role="paragraph">Depressive symptoms were assessed weekly with the use of the Patient Health Questionnaire 9 (PHQ-9); scores range from 0 to 27, with higher scores indicating greater depressive symptoms.</div></div><div role="doc-footnote" data-has="label"><div class="label">††</div><div id="t1fn8" role="paragraph">Life satisfaction was reported by the participants and was assessed with the use of the Treatment Effectiveness Assessment, which consists of four items; the scores for each item are summed, and total scores range from 4 to 40, with higher scores indicating greater satisfaction.</div></div></div></figcaption></figure></div><div role="paragraph">In stage 1, adherence to the assigned regimen was 75.1% in the naltrexone–bupropion group (63.9% to the oral regimen and 86.2% to the injection) and 83.5% in the placebo group (74.1% and 92.7%, respectively). In stage 2, adherence was 77.4% in the naltrexone–bupropion group (68.8% to the oral regimen and 86.4% to the injection) and 82.0% in the placebo group (75.1% and 89.2%, respectively).</div></section><section id="sec-2-2"><h3>Primary Outcome</h3><div role="paragraph">The primary outcome was a response, defined as at least three methamphetamine-negative urine samples out of a possible four samples obtained at the end of stage 1 (during week 5 through week 6) or the end of stage 2 (during week 11 through week 12). <a id="exam-tint-one-b"></a><a id="exam-tint-one-c"></a><a id="exam-tint-one-d"></a><span id="tint1" class="named-content" data-type="exam-tint" data-answer-ids="one-b one-c one-d">At the end of stage 1, a total of 16.5% (18 of 109 participants) in the naltrexone–bupropion group and 3.4% (10 of 294 participants) in the placebo group had a response. At the end of stage 2, a total of 11.4% (13 of 114 participants) in the naltrexone–bupropion group and 1.8% (2 of 111 participants) in the placebo group had a response (<a href="#t2">Table 2</a>). After weighting and combining the percentage of responses across the stages, we calculated that the overall weighted response was 13.6% in the naltrexone–bupropion group and 2.5% in the placebo group (<a href="#f2">Figure 2A</a>). The treatment effect, defined as the between-group difference in the overall weighted response, was 11.1 percentage points (lower boundary of the 95% confidence interval [CI], 6.3; Wald z-test statistic, 4.53; P&lt;0.001) (<a href="#t2">Table 2</a> and <a href="#f2">Figure 2A</a>).</span> <a href="#f2">Figure 2B</a> shows methamphetamine-negative urine results across trial visits; these results are consistent with those of the primary outcome. The overall treatment effects according to age, ethnic group, race, sex, and trial site are shown in Figure S2.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2020214_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2020214_f2.jpg"><img src="/cms/10.1056/NEJMoa2020214/asset/15ab8cd1-de04-4fb7-812b-1b8ffc8b88d0/assets/images/large/nejmoa2020214_f2.jpg" height="2478" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Responses and Methamphetamine-Negative Urine Samples.</div><div class="notes"><div role="doc-footnote">The primary outcome was a response, defined as at least three methamphetamine-negative urine samples out of a possible four obtained at the end of stage 1 (during weeks 5 through 6) or at the end of stage 2 (during weeks 11 through 12). We calculated the weighted average of the responses in each stage, and the difference between these results was used to determine the overall treatment effect. Panel A shows the percentage of participants with a response and the weighted average of the response in each trial group in the intention-to-treat population, which included all participants who underwent randomization in stage 1 and all participants who underwent randomization again in stage 2. Panel B shows the percentage of methamphetamine-negative urine samples according to stage and trial group in the intention-to-treat population. Placebo/naltrexone–bupropion refers to participants in the placebo group who did not have a response in stage 1 and were assigned to the naltrexone–bupropion group in stage 2. Placebo/placebo refers to participants in the placebo group who did not have a response in stage 1 and were assigned to the placebo group in stage 2. During the 12-week intervention period, participants visited the clinic twice per week, after which they had a visit at week 13 and week 16. The evaluation period was the last 2 weeks of each stage (each evaluation stage is shown in the shaded areas). The number of urine samples obtained indicates the number of urine drug screening results available according to trial group at each visit for all participants in the intention-to-treat population. Results of urine drug screenings obtained at the first visit during week 1 (the day of randomization) are not shown. Results of drug screenings obtained on or before the rerandomization date of each participant in stage 2 are not shown because these samples were obtained when participants were still receiving the regimen assigned in stage 1.</div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2020214_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2020214_t2.jpg"><img src="/cms/10.1056/NEJMoa2020214/asset/3cb5d0ad-9321-4fd3-8f65-db82847fb114/assets/images/large/nejmoa2020214_t2.jpg" height="1539" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Outcome</th><th class="txxx-borders" colspan="2"><span>Stage 1</span></th><th class="txxx-borders" colspan="2"><span>Stage 2</span></th><th class="txxr-borders" colspan="2"><span>Treatment Effect</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Naltrexone–Bupropion<br>(N=109)</th><th class="xxxx-borders">Placebo<br>(N=294)</th><th class="xxxx-borders">Naltrexone–Bupropion<br>(N=114)</th><th class="xxxx-borders">Placebo<br>(N=111)</th><th class="xxxx-borders">Weighted Difference</th><th class="xxxr-borders">95% CI</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Primary outcome — no. of participants (%)<a href="#t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">18 (16.5)</td><td class="xxxx-borders shading">10 (3.4)</td><td class="xxxx-borders shading">13 (11.4)</td><td class="xxxx-borders shading">2 (1.8)</td><td class="xxxx-borders shading">11.1±2.5</td><td class="xxxr-borders shading">—</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Secondary outcomes</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Methamphetamine-negative urine samples — %<a href="#t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">20.4±2.2</td><td class="xxxx-borders shading">12.3±1.6</td><td class="xxxx-borders shading">19.2±2.6</td><td class="xxxx-borders shading">13.4±1.5</td><td class="xxxx-borders shading">6.8±1.7</td><td class="xxxr-borders shading">3.5 to 10.1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Change in methamphetamine craving according to visual analogue scale<a href="#t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">−30.0±3.2</td><td class="xxxx-borders">−22.3±1.8</td><td class="xxxx-borders">−31.8±3.2</td><td class="xxxx-borders">−20.5±1.7</td><td class="xxxx-borders">−9.7±2.1</td><td class="xxxr-borders">−13.8 to −5.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Change in score on PHQ-9 depression scale<a href="#t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">−4.8±0.7</td><td class="xxxx-borders shading">−3.3±0.3</td><td class="xxxx-borders shading">−4.4±0.6</td><td class="xxxx-borders shading">−3.7±0.4</td><td class="xxxx-borders shading">−1.1±0.4</td><td class="xxxr-borders shading">−1.9 to −0.2</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Change in score on Treatment Effectiveness Assessment<a href="#t2fn4" role="doc-noteref">§</a><a href="#t2fn5" role="doc-noteref">¶</a></td><td class="xbxx-borders">6.5±1.5</td><td class="xbxx-borders">2.2±1.0</td><td class="xbxx-borders">6.2±1.5</td><td class="xbxx-borders">2.5±1.1</td><td class="xbxx-borders">4.0±0.9</td><td class="xbxr-borders">2.3 to 5.7</td></tr></tbody></table></div><figcaption><div class="caption">Primary and Secondary Outcomes in the Intention-to-Treat Population.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">Plus–minus values are means ±SE unless otherwise noted. The total number in stage 1 reflects the number of participants who underwent randomization. The total number in stage 2 reflects the number of participants in the placebo group who did not have a response in stage 1 and therefore underwent randomization again in stage 2. No clinical conclusions can be drawn from secondary outcomes because confidence intervals were not adjusted for multiple comparisons.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">The primary outcome was a response, defined as at least three methamphetamine-negative samples out of four obtained at the end of stage 1 or stage 2. The overall treatment effect was defined as the weighted average of the responses in the naltrexone–bupropion group minus the responses in the placebo group, reported in percentage points ±SE, determined with the use of a weight of 0.43 in stage 1 and a weight of 0.57 in stage 2. The formula for this calculation is provided in the statistical analysis plan, available with the <a href="#ap1">protocol</a> at NEJM.org. The Wald z-test statistic for the primary outcome was 4.530 (P&lt;0.001).</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t2fn3" role="paragraph">The percentage of methamphetamine-negative urine samples per participant was calculated by dividing the number of methamphetamine-negative urine samples obtained per stage by 12 (the number of expected samples per stage). The treatment effect is the between-group difference in the weighted average of negative urine samples, reported as percentage points ±SE.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t2fn4" role="paragraph">The changes in stage 1 reflect the change from baseline, and the changes in stage 2 reflect the change from the end of stage 1. The treatment effect is the between-group difference in the weighted average change in scores, reported as the difference in points ±SE.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t2fn5" role="paragraph">Data were available for 306 participants in stage 1 (74 in the naltrexone–bupropion group and 232 in the placebo group) and for 196 in stage 2 (98 in the naltrexone–bupropion group and 98 in the placebo group).</div></div></div></figcaption></figure></div><div role="paragraph">In the prespecified sensitivity analysis that included participants who provided all four of the expected urine samples in the last 2 weeks of each stage, 28.8% (15 of 52 participants) in the naltrexone–bupropion group and 5.1% (9 of 177 participants) in the placebo group had a response in stage 1; 16.2% (13 of 80 participants) in the naltrexone–bupropion group and 1.3% (1 of 75 participants) in the placebo group had a response in stage 2 (Table S1). The overall treatment effect in this population was an 18.7-percentage-point difference in response (95% CI, 11.6 to 25.8). In the prespecified sensitivity analysis that assumed equal weight for each stage, 16.5% (18 of 109 participants) in the naltrexone–bupropion group and 3.4% (10 of 294 participants) in the placebo group had a response in stage 1; 11.4% (13 of 114 participants) in the naltrexone–bupropion group and 1.8% (2 of 111 participants) in the placebo group had a response in stage 2. The overall treatment effect, under the assumption of equal weight for each stage, was an 11.4-percentage-point between-group difference in response (95% CI, 6.5 to 16.2).</div></section><section id="sec-2-3"><h3>Secondary Outcomes</h3><div role="paragraph">The percentage of participants with methamphetamine-negative urine samples was 20.4% in the naltrexone–bupropion group and 12.3% in the placebo group in stage 1 and 19.2% in the naltrexone–bupropion group and 13.4% in the placebo group in stage 2. The weighted difference between the two groups in the percentage of participants with methamphetamine-negative urine samples was 6.8 percentage points (<a href="#t2">Table 2</a>). The weighted difference between the naltrexone–bupropion group and the placebo group in weekly methamphetamine craving scores on the visual analogue scale was −9.7 points. The weighted difference between the naltrexone–bupropion group and the placebo group in weekly PHQ-9 scores was −1.1 points. The weighted difference between the naltrexone–bupropion group and the placebo group in participant-reported scores on the Treatment Effectiveness Assessment was 4.0 points. There was no prespecified plan for adjustments of confidence intervals for multiple comparisons of secondary outcomes, and no definite conclusions can be drawn from these results.</div></section><section id="sec-2-4"><h3>Safety</h3><div role="paragraph">Across both stages, 17 disparate serious adverse events occurred during the trial in the safety population (all participants who underwent randomization): 8 in the naltrexone–bupropion group and 9 in the placebo group. <a href="#t3">Table 3</a> includes 13 events that occurred in the intention-to-treat population. The other 4 events (3 in the naltrexone–bupropion group and 1 in the placebo group) occurred during stage 2 in the participants who did not undergo rerandomization. <a id="exam-tint-two-c"></a><span id="tint2" class="named-content" data-type="exam-tint" data-answer-ids="two-c">Adverse events were mostly mild or moderate (Table S2). Adverse events that occurred more frequently (P&lt;0.05) with naltrexone–bupropion than with placebo were nausea (37.6% vs. 15.3% in stage 1 and 28.1% vs. 7.2% in stage 2), vomiting (11.9% vs. 2.0% in stage 1 and 10.5% vs. 2.7% in stage 2), constipation (9.2% vs. 2.4% in stage 1), dry mouth (8.3% vs. 1.7% in stage 1), upper abdominal pain (4.6% vs. 0.3% in stage 1), dizziness (10.1% vs. 2.7% in stage 1), tremor (4.6% vs. 0.3% in stage 1), feeling jittery (3.7% vs. 0.7% in stage 1), malaise (3.7% vs. 0.3% in stage 1), hyperhidrosis (7.3% vs. 1.0% in stage 1), and decreased appetite (7.3% vs. 2.0% in stage 1).</span> Complete reports of adverse events are provided in <a href="#t3">Table 3</a> and Table S2.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2020214_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2020214_t3.jpg"><img src="/cms/10.1056/NEJMoa2020214/asset/d8d09485-9ca3-48a2-a4d2-fc7c3ff9e079/assets/images/large/nejmoa2020214_t3.jpg" height="3306" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders" colspan="3"><span>Stage 1</span></th><th class="txxr-borders" colspan="3"><span>Stage 2</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Naltrexone–Bupropion<br>(N=109)</th><th class="xxxx-borders">Placebo<br>(N=294)</th><th class="xxxx-borders">P Value</th><th class="xxxx-borders">Naltrexone–Bupropion<br>(N=114)</th><th class="xxxx-borders">Placebo<br>(N=111)</th><th class="xxxr-borders">P Value</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Participants with at least one serious adverse event — no. (%)<a href="#t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">1 (0.9)</td><td class="xxxx-borders shading">4 (1.4)</td><td class="xxxx-borders shading">1.00</td><td class="xxxx-borders shading">3 (2.6)</td><td class="xxxx-borders shading">4 (3.6)</td><td class="xxxr-borders shading">0.72</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Total no. of serious adverse events<a href="#t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">1</td><td class="xxxx-borders">4</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">4</td><td class="xxxx-borders">4</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Any adverse event — no. (%)</td><td class="xxxx-borders shading">99 (90.8)</td><td class="xxxx-borders shading">245 (83.3)</td><td class="xxxx-borders shading">0.08</td><td class="xxxx-borders shading">88 (77.2)</td><td class="xxxx-borders shading">77 (69.4)</td><td class="xxxr-borders shading">0.23</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Adverse events — no. (%)<a href="#t3fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Gastrointestinal events</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Nausea</td><td class="xxxx-borders">41 (37.6)</td><td class="xxxx-borders">45 (15.3)</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxx-borders">32 (28.1)</td><td class="xxxx-borders">8 (7.2)</td><td class="xxxr-borders">&lt;0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Diarrhea</td><td class="xxxx-borders shading">7 (6.4)</td><td class="xxxx-borders shading">18 (6.1)</td><td class="xxxx-borders shading">1.00</td><td class="xxxx-borders shading">6 (5.3)</td><td class="xxxx-borders shading">5 (4.5)</td><td class="xxxr-borders shading">1.00</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Vomiting</td><td class="xxxx-borders">13 (11.9)</td><td class="xxxx-borders">6 (2.0)</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxx-borders">12 (10.5)</td><td class="xxxx-borders">3 (2.7)</td><td class="xxxr-borders">0.03</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Constipation</td><td class="xxxx-borders shading">10 (9.2)</td><td class="xxxx-borders shading">7 (2.4)</td><td class="xxxx-borders shading">0.005</td><td class="xxxx-borders shading">2 (1.8)</td><td class="xxxx-borders shading">3 (2.7)</td><td class="xxxr-borders shading">0.68</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Dry mouth</td><td class="xxxx-borders">9 (8.3)</td><td class="xxxx-borders">5 (1.7)</td><td class="xxxx-borders">0.003</td><td class="xxxx-borders">1 (0.9)</td><td class="xxxx-borders">2 (1.8)</td><td class="xxxr-borders">0.62</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Upper abdominal pain</td><td class="xxxx-borders shading">5 (4.6)</td><td class="xxxx-borders shading">1 (0.3)</td><td class="xxxx-borders shading">0.006</td><td class="xxxx-borders shading">6 (5.3)</td><td class="xxxx-borders shading">3 (2.7)</td><td class="xxxr-borders shading">0.50</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Abdominal discomfort</td><td class="xxxx-borders">4 (3.7)</td><td class="xxxx-borders">5 (1.7)</td><td class="xxxx-borders">0.26</td><td class="xxxx-borders">1 (0.9)</td><td class="xxxx-borders">2 (1.8)</td><td class="xxxr-borders">0.62</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Nervous system symptoms and disorders</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Headache</td><td class="xxxx-borders">13 (11.9)</td><td class="xxxx-borders">68 (23.1)</td><td class="xxxx-borders">0.01</td><td class="xxxx-borders">11 (9.6)</td><td class="xxxx-borders">6 (5.4)</td><td class="xxxr-borders">0.31</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Dizziness</td><td class="xxxx-borders shading">11 (10.1)</td><td class="xxxx-borders shading">8 (2.7)</td><td class="xxxx-borders shading">0.006</td><td class="xxxx-borders shading">7 (6.1)</td><td class="xxxx-borders shading">1 (0.9)</td><td class="xxxr-borders shading">0.07</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Somnolence</td><td class="xxxx-borders">3 (2.8)</td><td class="xxxx-borders">10 (3.4)</td><td class="xxxx-borders">1.00</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (0.9)</td><td class="xxxr-borders">0.49</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Tremor</td><td class="xxxx-borders shading">5 (4.6)</td><td class="xxxx-borders shading">1 (0.3)</td><td class="xxxx-borders shading">0.006</td><td class="xxxx-borders shading">3 (2.6)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0.25</td></tr><tr data-type="row"><td class="xxlx-borders hanging13">Psychiatric symptoms and disorders</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Irritability</td><td class="xxxx-borders shading">6 (5.5)</td><td class="xxxx-borders shading">19 (6.5)</td><td class="xxxx-borders shading">0.82</td><td class="xxxx-borders shading">5 (4.4)</td><td class="xxxx-borders shading">4 (3.6)</td><td class="xxxr-borders shading">1.00</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Anxiety</td><td class="xxxx-borders">10 (9.2)</td><td class="xxxx-borders">14 (4.8)</td><td class="xxxx-borders">0.10</td><td class="xxxx-borders">1 (0.9)</td><td class="xxxx-borders">1 (0.9)</td><td class="xxxr-borders">1.00</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Insomnia</td><td class="xxxx-borders shading">6 (5.5)</td><td class="xxxx-borders shading">12 (4.1)</td><td class="xxxx-borders shading">0.59</td><td class="xxxx-borders shading">3 (2.6)</td><td class="xxxx-borders shading">1 (0.9)</td><td class="xxxr-borders shading">0.62</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Libido decreased</td><td class="xxxx-borders">4 (3.7)</td><td class="xxxx-borders">5 (1.7)</td><td class="xxxx-borders">0.26</td><td class="xxxx-borders">1 (0.9)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1.00</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Lability affected</td><td class="xxxx-borders shading">4 (3.7)</td><td class="xxxx-borders shading">4 (1.4)</td><td class="xxxx-borders shading">0.22</td><td class="xxxx-borders shading">2 (1.8)</td><td class="xxxx-borders shading">1 (0.9)</td><td class="xxxr-borders shading">1.00</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Depression</td><td class="xxxx-borders">2 (1.8)</td><td class="xxxx-borders">6 (2.0)</td><td class="xxxx-borders">1.00</td><td class="xxxx-borders">4 (3.5)</td><td class="xxxx-borders">4 (3.6)</td><td class="xxxr-borders">1.00</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">General disorders and injection-site reactions</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Fatigue</td><td class="xxxx-borders">8 (7.3)</td><td class="xxxx-borders">33 (11.2)</td><td class="xxxx-borders">0.35</td><td class="xxxx-borders">7 (6.1)</td><td class="xxxx-borders">8 (7.2)</td><td class="xxxr-borders">0.80</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Feeling jittery</td><td class="xxxx-borders shading">4 (3.7)</td><td class="xxxx-borders shading">2 (0.7)</td><td class="xxxx-borders shading">0.05</td><td class="xxxx-borders shading">1 (0.9)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1.00</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Malaise</td><td class="xxxx-borders">4 (3.7)</td><td class="xxxx-borders">1 (0.3)</td><td class="xxxx-borders">0.02</td><td class="xxxx-borders">1 (0.9)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1.00</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Metabolism and nutrition disorders</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Decreased appetite</td><td class="xxxx-borders">8 (7.3)</td><td class="xxxx-borders">6 (2.0)</td><td class="xxxx-borders">0.03</td><td class="xxxx-borders">3 (2.6)</td><td class="xxxx-borders">3 (2.7)</td><td class="xxxr-borders">1.00</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Musculoskeletal and connective tissue disorders</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Arthralgia</td><td class="xxxx-borders">4 (3.7)</td><td class="xxxx-borders">6 (2.0)</td><td class="xxxx-borders">0.47</td><td class="xxxx-borders">2 (1.8)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0.50</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Injury, poisoning, and procedural complications</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Contusion</td><td class="xxxx-borders">3 (2.8)</td><td class="xxxx-borders">5 (1.7)</td><td class="xxxx-borders">0.45</td><td class="xxxx-borders">0</td><td class="xxxx-borders">5 (4.5)</td><td class="xxxr-borders">0.03</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Skin and subcutaneous tissue disorders</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging23" data-xml-align="left">Hyperhidrosis</td><td class="xbxx-borders">8 (7.3)</td><td class="xbxx-borders">3 (1.0)</td><td class="xbxx-borders">0.002</td><td class="xbxx-borders">2 (1.8)</td><td class="xbxx-borders">0</td><td class="xbxr-borders">0.50</td></tr></tbody></table></div><figcaption><div class="caption">Adverse Events That Occurred during the Trial Period.<a href="#t3fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">Events shown for stage 1 include events that occurred before the start of stage 2 in the safety population (all participants who underwent randomization). Events shown for stage 2 include those that occurred on or after the date of rerandomization in participants in the intention-to-treat population (participants who underwent randomization again in stage 2). Adverse events were classified according to the preferred term and system organ class of the <i>Medical Dictionary for Regulatory Activities</i>, version 22.1.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t3fn2" role="paragraph">Of the 17 serious adverse events that occurred in the safety population (all participants who gave informed consent), 13 occurred in the intention-to-treat population and are reported in this table. Of the 13 serious adverse events, all except an event of seizure were recorded as serious because they resulted in either inpatient hospitalization or prolongation of an existing hospitalization. The additional 4 serious adverse events occurred after consent was given but before randomization; the events were hypertensive crisis (in 1 participant), genitourinary chlamydia infection (in 1 participant), neurosyphilis (in 1 participant), and appendicitis (in 1 participant). Four additional adverse events occurred in stage 2 in participants who did not undergo rerandomization (3 events in the naltrexone–bupropion group and 1 in the placebo group).</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t3fn3" role="paragraph">The serious adverse events in stage 1 were substance-induced psychosis, paranoia, pancreatitis, and seizure (in 1 participant each) in the placebo group, and gastroenteritis in 1 participant in the naltrexone–bupropion group. The serious adverse events in stage 2 were gastroenteritis shigella, pneumonia, urosepsis, and being the victim of a crime (in 1 participant each) in the placebo group, and homicidal ideation, cellulitis, neck pain, and hyperglycemia (in 1 participant each) in the naltrexone–bupropion group.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t3fn4" role="paragraph">The adverse events reported here are events of interest that occurred in 3% or more of participants in either stage in the naltrexone–bupropion group and events that had a P value of ≤0.05 for any pairwise comparison. Table S2 lists all adverse events that occurred during the trial in the safety population.</div></div></div></figcaption></figure></div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">The goal of this trial was to assess the effectiveness of the combination of naltrexone and extended-release bupropion in treating methamphetamine use disorder. The primary outcome was a response, defined as at least three methamphetamine-negative urine samples out of four samples obtained in the last 2 weeks of each stage. The response in each group was calculated by combining the weighted average of the responses in the two stages of the trial. The overall weighted response was 13.6% in the naltrexone–bupropion group and 2.5% in the placebo group. The results of the analyses of secondary outcomes, including the assessment of craving for methamphetamine and improvements in social functioning, were generally in the same direction as those of the primary outcome, but no definite conclusions can be drawn from these data because of the lack of a prespecified plan for multiplicity adjustment of confidence intervals for the point estimates of differences between the two trial groups.</div><div role="paragraph">Methamphetamine use disorder is a serious illness and is associated with medical conditions and mental health issues, marked functional impairment, and frequent relapses.<sup><a href="#core-r28" role="doc-biblioref" data-xml-rid="r28 r29" id="body-ref-r29" href-manipulated="true">28,29</a></sup> The participants in our trial were severely affected by methamphetamine use disorder, with almost daily use before entry into the trial. Our definition of a response included valid negative urine samples obtained after only 4 to 6 weeks in each stage of the trial. <a id="exam-tint-one-a"></a><span id="tint3" class="named-content" data-type="exam-tint" data-answer-ids="one-a">The percentage of participants who had a response in each stage of the trial was low; however, there was a significant difference in the weighted response (11.1 percentage points) between the naltrexone–bupropion group and the placebo group.</span> The number needed to treat in order for one patient to have a response under the assumptions in this trial is 9.</div><div role="paragraph"><a id="exam-tint-three-a"></a><a id="exam-tint-three-b"></a><a id="exam-tint-three-c"></a><a id="exam-tint-three-d"></a><span id="tint4" class="named-content" data-type="exam-tint" data-answer-ids="three-a three-b three-c three-d">The strengths of this trial include low attrition, high adherence to the trial regimen, a prospective evaluation to establish illness severity, and an objective primary outcome assessed on the basis of valid urine samples. However, the low attrition and high adherence may limit generalizability to clinical practice. Other limitations include the relatively low representation of women, although the male-to-female ratio in this trial is consistent with the difference in incidences of amphetamine use disorder between men and women in the United States.</span> Adherence to the oral regimen was determined on the basis of participant report and cannot be confirmed because ingestion was not observed by trial clinicians. The results of the trial may be difficult to explain to patients and practitioners because of the sequential parallel comparison design, which included enrichment of the stage 2 sample with the random reassignment of participants in the placebo group who did not have a response in stage 1 and the use of a weighted combination to analyze the response in each stage. This method was intended to enhance the likelihood of detecting efficacy of the combination treatment. Replication of our trial results in a more naturalistic effectiveness design could be a next step. An additional consideration in interpreting our trial results is the possible continuation of the trial, although the results of the interim sample-size reestimation analysis performed by the data and safety monitoring board showed a significant difference in outcomes between trial groups, and no adjustment was made in the significance level of the test of the primary outcome. The 12-week duration of a trial of a substance use disorder requires consideration of how the treatment can be adapted to practice.</div><div role="paragraph">In persons with moderate or severe methamphetamine use disorder, treatment with the combination of extended-release injectable naltrexone and daily oral extended-release bupropion over a period of 12 weeks resulted in a higher response than placebo.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="disclaimer" role="paragraph">The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or Alkermes.</div><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by awards (UG1DA020024 [to Dr. Trivedi], UG1DA013035 [to Dr. Nunes], UG1DA040316, UG1DA013727, and UG1DA015815) from the National Institute on Drug Abuse (<span class="named-content" data-type="funder">NIDA</span>) of the National Institutes of Health; and by the Department of Health and Human Services under contract numbers <span class="named-content" data-type="funder">HHS</span>N271201500065C (Clinical Coordinating Center, the Emmes Company) and <span class="named-content" data-type="funder">HHS</span>N271201400028C (Data and Statistics Center, the Emmes Company). Alkermes provided Vivitrol (naltrexone for extended-release injectable suspension) and matched placebo free of charge for use in this trial under a written agreement with <span class="named-content" data-type="funder">NIDA</span>.</div><div role="paragraph">Dr. Trivedi reports receiving consulting fees from AcademyHealth, Acadia, Alkermes, Allergan, Alto Neuroscience, Axsome Therapeutics, Boehringer Ingelheim, Vital Signs GreenLight, Janssen, Jazz Pharmaceuticals, Lundbeck, Medscape, Merck Sharp and Dohme, MSI Methylation Sciences, Myriad Neuroscience, Navitor, Otsuka, Oxford PharmaGenesis, Perception Neuroscience Holdings, Pharmerit International, Sage Therapeutics, Signant Health, and Takeda Pharmaceuticals America, fees for serving on a data and safety monitoring board from Applied Clinical Intelligence, fees for serving on an end-point review committee from Engage Health Media, and grant support, paid to his institution, from Janssen Research and Development, Johnson &amp; Johnson Health Care Systems, and the Patient-Centered Outcomes Research Institute; Dr. Walker, receiving donated drugs for use in a trial from Alkermes; Dr. Ling, receiving consulting fees from Indivior; Dr. Carmody, owning stock in CRISPR Therapeutics and Vertex; Dr. Rush, receiving consulting fees from COMPASS Pathways, Holmusk, Janssen Global Services, LivaNova, Neurocrine Biosciences, Otsuka America, and the Emmes Company; Dr. Nunes, receiving grant support, paid to his institution, from Brainsway USA and Reckitt Benckiser, donated drugs for use in a trial from Pear Therapeutics, and serving on advisory boards for Alkermes. No other potential conflict of interest relevant to this article was reported.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank the trial participants; the staff at the participating trial sites for their work in conducting the trial (Behavioral Health Services of Pickens County [Pickens, SC]; CODA [Portland, OR]; Hennepin County Medical Center–Berman Center for Research [Minneapolis]; New York State Psychiatric Institute–Substance Use Research Center [New York]; the Substance Use Research Unit at the San Francisco Department of Public Health [San Francisco]; the University of California, Los Angeles, Center for Behavioral Addiction Medicine [Los Angeles]; the Peter O’Donnell Jr. Brain Institute at the University of Texas Southwestern Medical Center [Dallas]; and the University of Texas Southwestern Medical Center [Dallas]); the trial collaborators (Matthew Wright and Eve Jelstrom [the Clinical Coordinating Center at the Emmes Company]; Catherine Mudrick, Ashley Case, and Jacquie King [the Data and Statistics Center at the Emmes Company]; Brien Hawley, Laura Schafner, and Gordon Kessler [AiCure]; and Angela Casey-Willingham, who helped monitor the implementation of the trial); Jennifer Sharpe Potter, Nora Volkow, and Taryn Mayes for providing input on earlier versions of the manuscript; and Georganna Carlock and Taryn Mayes for administrative assistance.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2020214_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2020214/suppl_file/nejmoa2020214_protocol.pdf" download="nejmoa2020214_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2020214_protocol.pdf" data-doi="10.1056/NEJMoa2020214">Download</a></li><li>1.96 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2020214_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2020214/suppl_file/nejmoa2020214_appendix.pdf" download="nejmoa2020214_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2020214_appendix.pdf" data-doi="10.1056/NEJMoa2020214">Download</a></li><li>691.24 KB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2020214_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2020214/suppl_file/nejmoa2020214_disclosures.pdf" download="nejmoa2020214_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2020214_disclosures.pdf" data-doi="10.1056/NEJMoa2020214">Download</a></li><li>761.50 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2020214_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2020214/suppl_file/nejmoa2020214_data-sharing.pdf" download="nejmoa2020214_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2020214_data-sharing.pdf" data-doi="10.1056/NEJMoa2020214">Download</a></li><li>71.80 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Hedegaard H, Bastian BA, Trinidad JP, Spencer MR, Warner M. Regional differences in the drugs most frequently involved in drug overdose deaths: United States, 2017. <em>Natl Vital Stat Rep</em> 2019;68:1-16.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32501207/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Regional+differences+in+the+drugs+most+frequently+involved+in+drug+overdose+deaths%3A+United+States%2C+2017&amp;publication_year=2019&amp;journal=Natl+Vital+Stat+Rep&amp;pages=1-16&amp;pmid=32501207" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Ellis MS, Kasper ZA, Cicero TJ. Twin epidemics: the surging rise of methamphetamine use in chronic opioid users. <em>Drug Alcohol Depend</em> 2018;193:14-20.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.drugalcdep.2018.08.029" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30326396/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000452578200003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Twin+epidemics%3A+the+surging+rise+of+methamphetamine+use+in+chronic+opioid+users.&amp;publication_year=2018&amp;journal=Drug+Alcohol+Depend&amp;pages=14-20&amp;doi=10.1016%2Fj.drugalcdep.2018.08.029&amp;pmid=30326396" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Ashok AH, Mizuno Y, Volkow ND, Howes OD. Association of stimulant use with dopaminergic alterations in users of cocaine, amphetamine, or methamphetamine: a systematic review and meta-analysis. <em>JAMA Psychiatry</em> 2017;74:511-519.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jamapsychiatry.2017.0135" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28297025/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000400464300015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Association+of+stimulant+use+with+dopaminergic+alterations+in+users+of+cocaine%2C+amphetamine%2C+or+methamphetamine%3A+a+systematic+review+and+meta-analysis.&amp;publication_year=2017&amp;journal=JAMA+Psychiatry&amp;pages=511-519&amp;doi=10.1001%2Fjamapsychiatry.2017.0135&amp;pmid=28297025" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Soares E, Pereira FC. Pharmacotherapeutic strategies for methamphetamine use disorder: mind the subgroups. <em>Expert Opin Pharmacother</em> 2019;20:2273-2293.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/14656566.2019.1681970" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31671001/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000493535700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pharmacotherapeutic+strategies+for+methamphetamine+use+disorder%3A+mind+the+subgroups.&amp;publication_year=2019&amp;journal=Expert+Opin+Pharmacother&amp;pages=2273-2293&amp;doi=10.1080%2F14656566.2019.1681970&amp;pmid=31671001" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Elkashef AM, Rawson RA, Anderson AL, et al. Bupropion for the treatment of methamphetamine dependence. <em>Neuropsychopharmacology</em> 2008;33:1162-1170.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/sj.npp.1301481" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17581531/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000253957600019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Bupropion+for+the+treatment+of+methamphetamine+dependence.&amp;publication_year=2008&amp;journal=Neuropsychopharmacology&amp;pages=1162-1170&amp;doi=10.1038%2Fsj.npp.1301481&amp;pmid=17581531" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Heinzerling KG, Swanson A-N, Hall TM, Yi Y, Wu Y, Shoptaw SJ. Randomized, placebo-controlled trial of bupropion in methamphetamine-dependent participants with less than daily methamphetamine use. <em>Addiction</em> 2014;109:1878-1886.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/add.12636" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24894963/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000343754500017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Randomized%2C+placebo-controlled+trial+of+bupropion+in+methamphetamine-dependent+participants+with+less+than+daily+methamphetamine+use.&amp;publication_year=2014&amp;journal=Addiction&amp;pages=1878-1886&amp;doi=10.1111%2Fadd.12636&amp;pmid=24894963" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Anderson AL, Li S-H, Markova D, et al. Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial. <em>Drug Alcohol Depend</em> 2015;150:170-174.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.drugalcdep.2015.01.036" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25818061/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000353600900023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Bupropion+for+the+treatment+of+methamphetamine+dependence+in+non-daily+users%3A+a+randomized%2C+double-blind%2C+placebo-controlled+trial.&amp;publication_year=2015&amp;journal=Drug+Alcohol+Depend&amp;pages=170-174&amp;doi=10.1016%2Fj.drugalcdep.2015.01.036&amp;pmid=25818061" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Runarsdottir V, Hansdottir I, Tyrfingsson T, et al. Extended-release injectable naltrexone (XR-NTX) with intensive psychosocial therapy for amphetamine-dependent persons seeking treatment: a placebo-controlled trial. <em>J Addict Med</em> 2017;11:197-204.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/ADM.0000000000000297" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28379861/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000402537100007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Extended-release+injectable+naltrexone+%28XR-NTX%29+with+intensive+psychosocial+therapy+for+amphetamine-dependent+persons+seeking+treatment%3A+a+placebo-controlled+trial.&amp;publication_year=2017&amp;journal=J+Addict+Med&amp;pages=197-204&amp;doi=10.1097%2FADM.0000000000000297&amp;pmid=28379861" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Jayaram-Lindström N, Hammarberg A, Beck O, Franck J. Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. <em>Am J Psychiatry</em> 2008;165:1442-1448.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1176/appi.ajp.2008.08020304" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18765480/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000260597000015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Naltrexone+for+the+treatment+of+amphetamine+dependence%3A+a+randomized%2C+placebo-controlled+trial.&amp;publication_year=2008&amp;journal=Am+J+Psychiatry&amp;pages=1442-1448&amp;doi=10.1176%2Fappi.ajp.2008.08020304&amp;pmid=18765480" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Ray LA, Bujarski S, Courtney KE, et al. The effects of naltrexone on subjective response to methamphetamine in a clinical sample: a double-blind, placebo-controlled laboratory study. <em>Neuropsychopharmacology</em> 2015;40:2347-2356.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/npp.2015.83" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25801501/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000359493700007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+effects+of+naltrexone+on+subjective+response+to+methamphetamine+in+a+clinical+sample%3A+a+double-blind%2C+placebo-controlled+laboratory+study.&amp;publication_year=2015&amp;journal=Neuropsychopharmacology&amp;pages=2347-2356&amp;doi=10.1038%2Fnpp.2015.83&amp;pmid=25801501" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and naltrexone </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of substances or cue-induced cravings. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Ballester J, Valentine G, Sofuoglu M. Pharmacological treatments for methamphetamine addiction: current status and future directions. <em>Expert Rev Clin Pharmacol</em> 2017;10:305-314.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27927042/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000396853100009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pharmacological+treatments+for+methamphetamine+addiction%3A+current+status+and+future+directions.&amp;publication_year=2017&amp;journal=Expert+Rev+Clin+Pharmacol&amp;pages=305-314&amp;pmid=27927042" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Chan B, Freeman M, Kondo K, et al. Pharmacotherapy for methamphetamine/amphetamine use disorder — a systematic review and meta-analysis. <em>Addiction</em> 2019;114:2122-2136.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/add.14755" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31328345/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000486258000001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pharmacotherapy+for+methamphetamine%2Famphetamine+use+disorder+%E2%80%94+a+systematic+review+and+meta-analysis.&amp;publication_year=2019&amp;journal=Addiction&amp;pages=2122-2136&amp;doi=10.1111%2Fadd.14755&amp;pmid=31328345" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Siefried KJ, Acheson LS, Lintzeris N, Ezard N. Pharmacological treatment of methamphetamine/amphetamine dependence: a systematic review. <em>CNS Drugs</em> 2020;34:337-365.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s40263-020-00711-x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32185696/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000520642500001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pharmacological+treatment+of+methamphetamine%2Famphetamine+dependence%3A+a+systematic+review.&amp;publication_year=2020&amp;journal=CNS+Drugs&amp;pages=337-365&amp;doi=10.1007%2Fs40263-020-00711-x&amp;pmid=32185696" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Banks ML, Smith DA, Blough BE. Methamphetamine-like discriminative stimulus effects of bupropion and its two hydroxy metabolites in male rhesus monkeys. <em>Behav Pharmacol</em> 2016;27:196-203.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/FBP.0000000000000224" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26886209/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000374892900014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Methamphetamine-like+discriminative+stimulus+effects+of+bupropion+and+its+two+hydroxy+metabolites+in+male+rhesus+monkeys.&amp;publication_year=2016&amp;journal=Behav+Pharmacol&amp;pages=196-203&amp;doi=10.1097%2FFBP.0000000000000224&amp;pmid=26886209" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Newton TF, Roache JD, De La Garza R II, et al. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. <em>Neuropsychopharmacology</em> 2006;31:1537-1544.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/sj.npp.1300979" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16319910/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000238418700019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Bupropion+reduces+methamphetamine-induced+subjective+effects+and+cue-induced+craving.&amp;publication_year=2006&amp;journal=Neuropsychopharmacology&amp;pages=1537-1544&amp;doi=10.1038%2Fsj.npp.1300979&amp;pmid=16319910" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Aboujaoude E, Salame WO. Naltrexone: a pan-addiction treatment? <em>CNS Drugs</em> 2016;30:719-733.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s40263-016-0373-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27401883/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000382155600005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Naltrexone%3A+a+pan-addiction+treatment%3F&amp;publication_year=2016&amp;journal=CNS+Drugs&amp;pages=719-733&amp;doi=10.1007%2Fs40263-016-0373-0&amp;pmid=27401883" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Hendershot CS, Wardell JD, Samokhvalov AV, Rehm J. Effects of naltrexone on alcohol self-administration and craving: meta-analysis of human laboratory studies. <em>Addict Biol</em> 2017;22:1515-1527.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/adb.12425" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27411969/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000413904600004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effects+of+naltrexone+on+alcohol+self-administration+and+craving%3A+meta-analysis+of+human+laboratory+studies.&amp;publication_year=2017&amp;journal=Addict+Biol&amp;pages=1515-1527&amp;doi=10.1111%2Fadb.12425&amp;pmid=27411969" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Roche DJO, Worley MJ, Courtney KE, et al. Naltrexone moderates the relationship between cue-induced craving and subjective response to methamphetamine in individuals with methamphetamine use disorder. <em>Psychopharmacology (Berl)</em> 2017;234:1997-2007.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s00213-017-4607-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28357460/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000403476500007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Naltrexone+moderates+the+relationship+between+cue-induced+craving+and+subjective+response+to+methamphetamine+in+individuals+with+methamphetamine+use+disorder.&amp;publication_year=2017&amp;journal=Psychopharmacology+%28Berl%29&amp;pages=1997-2007&amp;doi=10.1007%2Fs00213-017-4607-8&amp;pmid=28357460" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Mooney LJ, Hillhouse MP, Thomas C, et al. Utilizing a two-stage design to investigate the safety and potential efficacy of monthly naltrexone plus once-daily bupropion as a treatment for methamphetamine use disorder. <em>J Addict Med</em> 2016;10:236-243.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r19" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/ADM.0000000000000218" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27379819/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000380842500004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Utilizing+a+two-stage+design+to+investigate+the+safety+and+potential+efficacy+of+monthly+naltrexone+plus+once-daily+bupropion+as+a+treatment+for+methamphetamine+use+disorder.&amp;publication_year=2016&amp;journal=J+Addict+Med&amp;pages=236-243&amp;doi=10.1097%2FADM.0000000000000218&amp;pmid=27379819" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r19" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] of severe methamphetamine use disorder. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] on the basis of a small pilot study. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Fava M, Evins AE, Dorer DJ, Schoenfeld DA. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. <em>Psychother Psychosom</em> 2003;72:115-127.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r20" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1159/000069738" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/12707478/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000182854300002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+problem+of+the+placebo+response+in+clinical+trials+for+psychiatric+disorders%3A+culprits%2C+possible+remedies%2C+and+a+novel+study+design+approach.&amp;publication_year=2003&amp;journal=Psychother+Psychosom&amp;pages=115-127&amp;doi=10.1159%2F000069738&amp;pmid=12707478" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r20" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r21-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] a sequential parallel comparison design, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] sequential parallel comparison design. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Chen Y-F, Yang Y, Hung HMJ, Wang S-J. Evaluation of performance of some enrichment designs dealing with high placebo response in psychiatric clinical trials. <em>Contemp Clin Trials</em> 2011;32:592-604.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r21" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cct.2011.04.006" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21540126/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000292226500020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Evaluation+of+performance+of+some+enrichment+designs+dealing+with+high+placebo+response+in+psychiatric+clinical+trials.&amp;publication_year=2011&amp;journal=Contemp+Clin+Trials&amp;pages=592-604&amp;doi=10.1016%2Fj.cct.2011.04.006&amp;pmid=21540126" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r21" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r21-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] a sequential parallel comparison design, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] sequential parallel comparison design. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Tamura RN, Huang X. An examination of the efficiency of the sequential parallel design in psychiatric clinical trials. <em>Clin Trials</em> 2007;4:309-317.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r22" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1177/1740774507081217" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17848492/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000250185100002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=An+examination+of+the+efficiency+of+the+sequential+parallel+design+in+psychiatric+clinical+trials.&amp;publication_year=2007&amp;journal=Clin+Trials&amp;pages=309-317&amp;doi=10.1177%2F1740774507081217&amp;pmid=17848492" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r22" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r22-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] the full text of this article at NEJM.org). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] According to the sample-size calculation, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] use of a one-sided Wald z-test statistic </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">McHugh RK, Fitzmaurice GM, Carroll KM, et al. Assessing craving and its relationship to subsequent prescription opioid use among treatment-seeking prescription opioid dependent patients. <em>Drug Alcohol Depend</em> 2014;145:121-126.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.drugalcdep.2014.10.002" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25454409/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000347512700011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Assessing+craving+and+its+relationship+to+subsequent+prescription+opioid+use+among+treatment-seeking+prescription+opioid+dependent+patients.&amp;publication_year=2014&amp;journal=Drug+Alcohol+Depend&amp;pages=121-126&amp;doi=10.1016%2Fj.drugalcdep.2014.10.002&amp;pmid=25454409" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. <em>J Gen Intern Med</em> 2001;16:606-613.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1046/j.1525-1497.2001.016009606.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11556941/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000171184700005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+PHQ-9%3A+validity+of+a+brief+depression+severity+measure.&amp;publication_year=2001&amp;journal=J+Gen+Intern+Med&amp;pages=606-613&amp;doi=10.1046%2Fj.1525-1497.2001.016009606.x&amp;pmid=11556941" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Ling W, Farabee D, Liepa D, Wu L-T. The Treatment Effectiveness Assessment (TEA): an efficient, patient-centered instrument for evaluating progress in recovery from addiction. <em>Subst Abuse Rehabil</em> 2012;3:129-136.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2147/SAR.S38902" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23580868/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+Treatment+Effectiveness+Assessment+%28TEA%29%3A+an+efficient%2C+patient-centered+instrument+for+evaluating+progress+in+recovery+from+addiction.&amp;publication_year=2012&amp;journal=Subst+Abuse+Rehabil&amp;pages=129-136&amp;doi=10.2147%2FSAR.S38902&amp;pmid=23580868" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">Trivedi MH, Wisniewski SR, Morris DW, et al. Concise Associated Symptoms Tracking Scale: a brief self-report and clinician rating of symptoms associated with suicidality. <em>J Clin Psychiatry</em> 2011;72:765-774.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.4088/JCP.11m06840" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21733477/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000292340900005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Concise+Associated+Symptoms+Tracking+Scale%3A+a+brief+self-report+and+clinician+rating+of+symptoms+associated+with+suicidality.&amp;publication_year=2011&amp;journal=J+Clin+Psychiatry&amp;pages=765-774&amp;doi=10.4088%2FJCP.11m06840&amp;pmid=21733477" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="r27" class="citations"><div class="citation"><div class="citation-content">Doros G, Pencina M, Rybin D, Meisner A, Fava M. A repeated measures model for analysis of continuous outcomes in sequential parallel comparison design studies. <em>Stat Med</em> 2013;32:2767-2789.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/sim.5728" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23355369/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000320400900005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+repeated+measures+model+for+analysis+of+continuous+outcomes+in+sequential+parallel+comparison+design+studies.&amp;publication_year=2013&amp;journal=Stat+Med&amp;pages=2767-2789&amp;doi=10.1002%2Fsim.5728&amp;pmid=23355369" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="r28" class="citations"><div class="citation"><div class="citation-content">Courtney KE, Ray LA. Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology, and treatment literature. <em>Drug Alcohol Depend</em> 2014;143:11-21.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.drugalcdep.2014.08.003" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25176528/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000342871100002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Methamphetamine%3A+an+update+on+epidemiology%2C+pharmacology%2C+clinical+phenomenology%2C+and+treatment+literature.&amp;publication_year=2014&amp;journal=Drug+Alcohol+Depend&amp;pages=11-21&amp;doi=10.1016%2Fj.drugalcdep.2014.08.003&amp;pmid=25176528" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="r29" class="citations"><div class="citation"><div class="citation-content">Panenka WJ, Procyshyn RM, Lecomte T, et al. Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings. <em>Drug Alcohol Depend</em> 2013;129:167-179.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.drugalcdep.2012.11.016" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23273775/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000318754700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Methamphetamine+use%3A+a+comprehensive+review+of+molecular%2C+preclinical+and+clinical+findings.&amp;publication_year=2013&amp;journal=Drug+Alcohol+Depend&amp;pages=167-179&amp;doi=10.1016%2Fj.drugalcdep.2012.11.016&amp;pmid=23273775" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/384/2"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">384</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">2</span></span> • <span property="datePublished">January 14, 2021</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">140</span>-<span property="pageEnd">153</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2021 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: January 13, 2021</div><div><b class="core-label">Published in issue</b>: January 14, 2021</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/addiction" alt="View article keyword Addiction" data-interactiontype="article_recirculation_click">Addiction</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/neurology-neurosurgery-general" alt="View article keyword Neurology/Neurosurgery General" data-interactiontype="article_recirculation_click">Neurology/Neurosurgery General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Madhukar H.</span> <span property="familyName">Trivedi</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Robrina</span> <span property="familyName">Walker</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Walter</span> <span property="familyName">Ling</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Adriane</span> <span property="familyName">dela Cruz</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Gaurav</span> <span property="familyName">Sharma</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Thomas</span> <span property="familyName">Carmody</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Udi E.</span> <span property="familyName">Ghitza</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Aimee</span> <span property="familyName">Wahle</span>, <span property="honorificSuffix">M.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Mora</span> <span property="familyName">Kim</span>, <span property="honorificSuffix">M.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Kathy</span> <span property="familyName">Shores-Wilson</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Steven</span> <span property="familyName">Sparenborg</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Phillip</span> <span property="familyName">Coffin</span>, <span property="honorificSuffix">M.D., M.I.A.</span></span>, <span property="author" typeof="Person"><span property="givenName">Joy</span> <span property="familyName">Schmitz</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Katharina</span> <span property="familyName">Wiest</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Gavin</span> <span property="familyName">Bart</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Susan C.</span> <span property="familyName">Sonne</span>, <span property="honorificSuffix">Pharm.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sidarth</span> <span property="familyName">Wakhlu</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">A. John</span> <span property="familyName">Rush</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Edward V.</span> <span property="familyName">Nunes</span>, <span property="honorificSuffix">M.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Steven</span> <span property="familyName">Shoptaw</span>, <span property="honorificSuffix">Ph.D.</span></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the Peter O’Donnell Jr. Brain Institute at the University of Texas Southwestern Medical Center (M.H.T.) and the University of Texas Southwestern Medical Center (R.W., A.C., T.C., M.K., K.S.-W., S.W.), Dallas, the University of Texas Health Science Center at Houston, Houston (J.S.), and Texas Tech University, Permian Basin, Odessa (A.J.R.); the University of California, Los Angeles, Los Angeles (W.L., S. Shoptaw); the Emmes Company, Rockville (G.S., A.W.), and the National Institute on Drug Abuse Center for the Clinical Trials Network (U.E.G., S. Sparenborg [retired]), Rockville — both in Maryland; the San Francisco Department of Public Health and the University of California, San Francisco, San Francisco (P.C.); CODA, Portland, OR (K.W.); Hennepin Healthcare, University of Minnesota, Minneapolis (G.B.); Medical University of South Carolina, Charleston (S.C.S.); Duke–National University of Singapore, Singapore (A.J.R.); Duke Medical School, Durham, NC (A.J.R.); and Columbia University, New York (E.V.N.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. Trivedi at the University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-9119, or at <a href="mailto:madhukar.trivedi@utsouthwestern.edu">madhukar.trivedi@utsouthwestern.edu</a>.</div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">178</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2020214" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="9c21730e-8b97-6545-87a9-1a65ab28f95f"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=97626942" style="display:inline-block;">
                <img alt="Article has an altmetric score of 480" src="https://badges.altmetric.com/?size=320&amp;score=480&amp;types=mabcrtfu" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=97626942">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_9c21730e-8b97-6545-87a9-1a65ab28f95f" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=97626942&amp;tab=news">
          Picked up by <b>45</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=97626942&amp;tab=blogs">
          Blogged by <b>6</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=97626942&amp;tab=twitter">
          Posted by <b>148</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #f27700;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=97626942&amp;tab=patents">
          Referenced in <b>1</b> patents
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=97626942&amp;tab=facebook">
          On <b>3</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #D5E8F0;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=97626942&amp;tab=reddit">
          Reddited by <b>3</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #A1E3E4;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=97626942&amp;tab=guidelines">
          Referenced in <b>1</b> clinical guideline sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #70B1FF;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=97626942&amp;tab=bluesky">
          Referenced by <b>7</b> Bluesky users
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>281</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d665ab0632a444-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2020214"> <input type="hidden" name="downloadFileName" value="csp_384_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.384.issue-2%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2020214" data-lazyload="false" data-total="178" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Linda Peng, </li><li class="list-inline-item cited-by__entry__author">Erin Stack, </li><li class="list-inline-item cited-by__entry__author">Alexis Cooke, </li><li class="list-inline-item cited-by__entry__author">Bryan Hartzler, </li><li class="list-inline-item cited-by__entry__author">Ryan Cook, </li><li class="list-inline-item cited-by__entry__author">Gillian Leichtling, </li><li class="list-inline-item cited-by__entry__author">Christi Hildebran, </li><li class="list-inline-item cited-by__entry__author">Judith Leahy, </li><li class="list-inline-item cited-by__entry__author">Kelsey Smith Payne, </li><li class="list-inline-item cited-by__entry__author">Lynn Kunkel, </li><li class="list-inline-item cited-by__entry__author">Kim Hoffman, </li><li class="list-inline-item cited-by__entry__author">P. Todd Korthuis, </li></ul><span class="cited-by__entry__title">Centering peers in design and training for a peer-delivered contingency management program for self-identified harm reduction and treatment goals, </span><span class="cited-by__entry__series-title">Harm Reduction Journal, </span><span class="cited-by__entry__volume"><strong>22</strong>, </span><span class="cited-by__entry__issue">S1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1186/s12954-025-01213-z" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1186/s12954-025-01213-z</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1186/s12954-025-01213-z" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Ibrahim M. Sablaban, </li><li class="list-inline-item cited-by__entry__author">Hassan Barada, </li></ul><span class="cited-by__entry__title">Substance Use Disorders, </span><span class="cited-by__entry__series-title">Advances in Psychiatry and Behavioral Health, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.ypsc.2025.04.002" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.ypsc.2025.04.002</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.ypsc.2025.04.002" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Chukwuemeka N. Okafor, </li><li class="list-inline-item cited-by__entry__author">Jin H Yoon, </li><li class="list-inline-item cited-by__entry__author">Ducel Jean-Berluche, </li><li class="list-inline-item cited-by__entry__author">Taryn L. Mayes, </li><li class="list-inline-item cited-by__entry__author">Steve Shoptaw, </li><li class="list-inline-item cited-by__entry__author">Madhukar H. Trivedi, </li><li class="list-inline-item cited-by__entry__author">Jennifer S Potter, </li><li class="list-inline-item cited-by__entry__author">Joy Schmitz, </li></ul><span class="cited-by__entry__title">Exploring the Impact of Reduction in Methamphetamine Use on Sexual Risk Behaviors Among Men Who Have Sex with Men and Women: Findings from the ADAPT- 2 Trial, </span><span class="cited-by__entry__series-title">International Journal of Behavioral Medicine, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1007/s12529-025-10364-z" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1007/s12529-025-10364-z</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1007/s12529-025-10364-z" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Maksym Skrypnyk, </li><li class="list-inline-item cited-by__entry__author">Roman Skrypnyk, </li><li class="list-inline-item cited-by__entry__author">Tatiana Petrushanko, </li><li class="list-inline-item cited-by__entry__author">Margarita Skikevych, </li><li class="list-inline-item cited-by__entry__author">Vladymyr Petrushanko, </li><li class="list-inline-item cited-by__entry__author">Igor Skrypnyk, </li></ul><span class="cited-by__entry__title">Case Report: Unusual oral cavity changes associated with methamphetamine abuse, </span><span class="cited-by__entry__series-title">Frontiers in Public Health, </span><span class="cited-by__entry__volume"><strong>13</strong>, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3389/fpubh.2025.1473584" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3389/fpubh.2025.1473584</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3389/fpubh.2025.1473584" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Huiqiong Deng, </li><li class="list-inline-item cited-by__entry__author">Mastaneh Nikravesh, </li><li class="list-inline-item cited-by__entry__author">Amer Raheemullah, </li><li class="list-inline-item cited-by__entry__author">Steven Tate, </li></ul><span class="cited-by__entry__title">Using inpatient addiction consult service via telehealth to improve pharmacotherapy initiation: An observational study, </span><span class="cited-by__entry__series-title">Journal of Telemedicine and Telecare, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1177/1357633X251319851" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1177/1357633X251319851</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1177/1357633X251319851" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Lisa R Metsch, </li><li class="list-inline-item cited-by__entry__author">Daniel J Feaster, </li><li class="list-inline-item cited-by__entry__author">Lauren K Gooden, </li><li class="list-inline-item cited-by__entry__author">Yue Pan, </li><li class="list-inline-item cited-by__entry__author">Carrigan L Parish, </li><li class="list-inline-item cited-by__entry__author">Drenna Waldrop, </li><li class="list-inline-item cited-by__entry__author">Allan Rodriguez, </li><li class="list-inline-item cited-by__entry__author">Jonathan A Colasanti, </li><li class="list-inline-item cited-by__entry__author">Pedro C Castellón, </li><li class="list-inline-item cited-by__entry__author">Wendy S Armstrong, </li><li class="list-inline-item cited-by__entry__author">Michael Miller, </li><li class="list-inline-item cited-by__entry__author">Christin Root, </li><li class="list-inline-item cited-by__entry__author">Margaret R Pereyra, </li><li class="list-inline-item cited-by__entry__author">Carlos del Rio, </li></ul><span class="cited-by__entry__title">Project RETAIN: Providing Integrated Care for People With HIV Who Use Cocaine, </span><span class="cited-by__entry__series-title">Open Forum Infectious Diseases, </span><span class="cited-by__entry__volume"><strong>12</strong>, </span><span class="cited-by__entry__issue">4, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1093/ofid/ofaf104" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1093/ofid/ofaf104</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1093/ofid/ofaf104" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Matisyahu Shulman, </li><li class="list-inline-item cited-by__entry__author">Tse-Hwei Choo, </li><li class="list-inline-item cited-by__entry__author">Kaitlyn Ohrtman, </li><li class="list-inline-item cited-by__entry__author">Martina Pavlicova, </li><li class="list-inline-item cited-by__entry__author">John Rotrosen, </li><li class="list-inline-item cited-by__entry__author">Edward V. Nunes, </li></ul><span class="cited-by__entry__title">Effects of randomization to buprenorphine or naltrexone for OUD on cannabis use outcomes: A secondary analysis of the X:BOT trial, </span><span class="cited-by__entry__series-title">Drug and Alcohol Dependence, </span><span class="cited-by__entry__volume"><strong>268</strong>, </span><span class="cited-by__entry__page-range">(112550), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.drugalcdep.2025.112550" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.drugalcdep.2025.112550</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.drugalcdep.2025.112550" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Ramisha Khan, </li><li class="list-inline-item cited-by__entry__author">Alyna Turner, </li><li class="list-inline-item cited-by__entry__author">Michael Berk, </li><li class="list-inline-item cited-by__entry__author">Ken Walder, </li><li class="list-inline-item cited-by__entry__author">Susan Rossell, </li><li class="list-inline-item cited-by__entry__author">Alexandre A. Guerin, </li><li class="list-inline-item cited-by__entry__author">Jee Hyun Kim, </li></ul><span class="cited-by__entry__title">Genes, Cognition, and Their Interplay in Methamphetamine Use Disorder, </span><span class="cited-by__entry__series-title">Biomolecules, </span><span class="cited-by__entry__volume"><strong>15</strong>, </span><span class="cited-by__entry__issue">2, </span><span class="cited-by__entry__page-range">(306), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3390/biom15020306" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3390/biom15020306</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3390/biom15020306" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Kathryn Fletcher, </li><li class="list-inline-item cited-by__entry__author">Nadine Ezard, </li><li class="list-inline-item cited-by__entry__author">Krista J Siefried, </li><li class="list-inline-item cited-by__entry__author">Harriet MacDonald, </li><li class="list-inline-item cited-by__entry__author">Liam Acheson, </li><li class="list-inline-item cited-by__entry__author">Gillinder Bedi, </li><li class="list-inline-item cited-by__entry__author">Alexandre Guerin, </li><li class="list-inline-item cited-by__entry__author">Elizabeth Knock, </li><li class="list-inline-item cited-by__entry__author">Michael Millard, </li><li class="list-inline-item cited-by__entry__author">Robert May, </li><li class="list-inline-item cited-by__entry__author">Jonathan Brett, </li><li class="list-inline-item cited-by__entry__author">Jess Doumany, </li><li class="list-inline-item cited-by__entry__author">Celia Morgan, </li><li class="list-inline-item cited-by__entry__author">Brendan Clifford, </li></ul><span class="cited-by__entry__title">Protocol of an open-label safety and feasibility pilot study of ketamine-assisted psychotherapy for methamphetamine use disorder (the KAPPA trial), </span><span class="cited-by__entry__series-title">BMJ Open, </span><span class="cited-by__entry__volume"><strong>15</strong>, </span><span class="cited-by__entry__issue">2, </span><span class="cited-by__entry__page-range">(e092504), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1136/bmjopen-2024-092504" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1136/bmjopen-2024-092504</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1136/bmjopen-2024-092504" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Krista J Siefried, </li><li class="list-inline-item cited-by__entry__author">Liam Acheson, </li><li class="list-inline-item cited-by__entry__author">Brendan Clifford, </li><li class="list-inline-item cited-by__entry__author">Carl Moller, </li><li class="list-inline-item cited-by__entry__author">Jonathan Brett, </li><li class="list-inline-item cited-by__entry__author">Michael Christmass, </li><li class="list-inline-item cited-by__entry__author">Adrian John Dunlop, </li><li class="list-inline-item cited-by__entry__author">Paul S Haber, </li><li class="list-inline-item cited-by__entry__author">Didier Jutras-Aswad, </li><li class="list-inline-item cited-by__entry__author">Nicholas Lintzeris, </li><li class="list-inline-item cited-by__entry__author">Kirsten Morley, </li><li class="list-inline-item cited-by__entry__author">Steven Shoptaw, </li><li class="list-inline-item cited-by__entry__author">Madhukar H Trivedi, </li><li class="list-inline-item cited-by__entry__author">Nadine Ezard, </li></ul><span class="cited-by__entry__title">Trial protocol of an open-label pilot study of oral naltrexone–bupropion combination pharmacotherapy for the treatment of methamphetamine use disorder (the NABU trial), </span><span class="cited-by__entry__series-title">BMJ Open, </span><span class="cited-by__entry__volume"><strong>15</strong>, </span><span class="cited-by__entry__issue">2, </span><span class="cited-by__entry__page-range">(e092032), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1136/bmjopen-2024-092032" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1136/bmjopen-2024-092032</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1136/bmjopen-2024-092032" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.384.issue-2%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2020214" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2020214" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2020214" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2020214.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2020214_f1.jpg"><img src="/cms/10.1056/NEJMoa2020214/asset/29a29702-674e-4ad1-b557-0e0c4d7ccae7/assets/images/large/nejmoa2020214_f1.jpg" height="3213" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Screening and Randomization.</div><div class="notes"><div role="doc-footnote">Participants may have had more than one reason for not undergoing randomization in stage 1. The analysis of the primary outcome was performed in the intention-to-treat population, which included all participants who underwent randomization in stage 1 and all participants who underwent randomization again in stage 2.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2020214_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2020214_f2.jpg"><img src="/cms/10.1056/NEJMoa2020214/asset/15ab8cd1-de04-4fb7-812b-1b8ffc8b88d0/assets/images/large/nejmoa2020214_f2.jpg" height="2478" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Responses and Methamphetamine-Negative Urine Samples.</div><div class="notes"><div role="doc-footnote">The primary outcome was a response, defined as at least three methamphetamine-negative urine samples out of a possible four obtained at the end of stage 1 (during weeks 5 through 6) or at the end of stage 2 (during weeks 11 through 12). We calculated the weighted average of the responses in each stage, and the difference between these results was used to determine the overall treatment effect. Panel A shows the percentage of participants with a response and the weighted average of the response in each trial group in the intention-to-treat population, which included all participants who underwent randomization in stage 1 and all participants who underwent randomization again in stage 2. Panel B shows the percentage of methamphetamine-negative urine samples according to stage and trial group in the intention-to-treat population. Placebo/naltrexone–bupropion refers to participants in the placebo group who did not have a response in stage 1 and were assigned to the naltrexone–bupropion group in stage 2. Placebo/placebo refers to participants in the placebo group who did not have a response in stage 1 and were assigned to the placebo group in stage 2. During the 12-week intervention period, participants visited the clinic twice per week, after which they had a visit at week 13 and week 16. The evaluation period was the last 2 weeks of each stage (each evaluation stage is shown in the shaded areas). The number of urine samples obtained indicates the number of urine drug screening results available according to trial group at each visit for all participants in the intention-to-treat population. Results of urine drug screenings obtained at the first visit during week 1 (the day of randomization) are not shown. Results of drug screenings obtained on or before the rerandomization date of each participant in stage 2 are not shown because these samples were obtained when participants were still receiving the regimen assigned in stage 1.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2020214_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2020214_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2020214/asset/6a2a379b-f205-464b-8682-a7459b4d9d80/assets/images/large/nejmoa2020214_t1.jpg" height="3001" width="2615" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">All Participants</th><th class="txxx-borders" colspan="2"><span>Stage 1</span></th><th class="txxr-borders" colspan="2"><span>Stage 2</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Total<a href="#core-t1fn2" role="doc-noteref">†</a><br>(N=403)</th><th class="xxxx-borders">Naltrexone–Bupropion<br>(N=109)</th><th class="xxxx-borders">Placebo<br>(N=294)</th><th class="xxxx-borders">Naltrexone–Bupropion<br>(N=114)</th><th class="xxxr-borders">Placebo<br>(N=111)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Demographic characteristics</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Male — no. (%)</td><td class="xxxx-borders">277 (68.7)</td><td class="xxxx-borders">78 (71.6)</td><td class="xxxx-borders">199 (67.7)</td><td class="xxxx-borders">78 (68.4)</td><td class="xxxr-borders">79 (71.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Age — yr</td><td class="xxxx-borders shading">41.0±10.1</td><td class="xxxx-borders shading">41.0±10.6</td><td class="xxxx-borders shading">41.0±10.0</td><td class="xxxx-borders shading">41.0±10.5</td><td class="xxxr-borders shading">42.0±9.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Hispanic or Latino ethnic group — no. (%)<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">55 (13.6)</td><td class="xxxx-borders">13 (11.9)</td><td class="xxxx-borders">42 (14.3)</td><td class="xxxx-borders">20 (17.5)</td><td class="xxxr-borders">18 (16.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Race or ethnic group — no. (%)<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">White</td><td class="xxxx-borders">287 (71.2)</td><td class="xxxx-borders">82 (75.2)</td><td class="xxxx-borders">205 (69.7)</td><td class="xxxx-borders">84 (73.7)</td><td class="xxxr-borders">69 (62.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Black</td><td class="xxxx-borders shading">48 (11.9)</td><td class="xxxx-borders shading">10 (9.2)</td><td class="xxxx-borders shading">38 (12.9)</td><td class="xxxx-borders shading">8 (7.0)</td><td class="xxxr-borders shading">22 (19.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Other</td><td class="xxxx-borders">68 (16.9)</td><td class="xxxx-borders">17 (15.6)</td><td class="xxxx-borders">51 (17.3)</td><td class="xxxx-borders">22 (19.3)</td><td class="xxxr-borders">20 (18.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">High school diploma, GED, or lower education level — no. (%)</td><td class="xxxx-borders shading">142 (35.2)</td><td class="xxxx-borders shading">39 (35.8)</td><td class="xxxx-borders shading">103 (35.0)</td><td class="xxxx-borders shading">36 (31.6)</td><td class="xxxr-borders shading">33 (29.7)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Marital status — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Married or living with partner</td><td class="xxxx-borders shading">93 (23.1)</td><td class="xxxx-borders shading">26 (23.9)</td><td class="xxxx-borders shading">67 (22.8)</td><td class="xxxx-borders shading">25 (21.9)</td><td class="xxxr-borders shading">25 (22.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Never married</td><td class="xxxx-borders">204 (50.6)</td><td class="xxxx-borders">49 (45.0)</td><td class="xxxx-borders">155 (52.7)</td><td class="xxxx-borders">60 (52.6)</td><td class="xxxr-borders">59 (53.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Divorced, separated, widowed, or unknown — no. (%)</td><td class="xxxx-borders shading">106 (26.3)</td><td class="xxxx-borders shading">34 (31.2)</td><td class="xxxx-borders shading">72 (24.5)</td><td class="xxxx-borders shading">29 (25.4)</td><td class="xxxr-borders shading">27 (24.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Employed — no. (%)<a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">156 (38.7)</td><td class="xxxx-borders">43 (39.4)</td><td class="xxxx-borders">113 (38.4)</td><td class="xxxx-borders">46 (40.4)</td><td class="xxxr-borders">44 (39.6)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Methamphetamine use</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">No. of days that methamphetamine was used in the 30 days before consent<a href="#core-t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">26.7±4.1</td><td class="xxxx-borders">27.0±3.9</td><td class="xxxx-borders">26.5±4.2</td><td class="xxxx-borders">26.7±4.1</td><td class="xxxr-borders">26.1±4.3</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Most frequent route of methamphetamine use — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Smoking</td><td class="xxxx-borders">293 (72.7)</td><td class="xxxx-borders">80 (73.4)</td><td class="xxxx-borders">213 (72.4)</td><td class="xxxx-borders">83 (72.8)</td><td class="xxxr-borders">79 (71.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Intravenous</td><td class="xxxx-borders shading">77 (19.1)</td><td class="xxxx-borders shading">23 (21.1)</td><td class="xxxx-borders shading">54 (18.4)</td><td class="xxxx-borders shading">21 (18.4)</td><td class="xxxr-borders shading">22 (19.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Nasal or oral</td><td class="xxxx-borders">33 (8.2)</td><td class="xxxx-borders">6 (5.5)</td><td class="xxxx-borders">27 (9.2)</td><td class="xxxx-borders">10 (8.8)</td><td class="xxxr-borders">10 (9.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Participants reporting intravenous methamphetamine use ≥1 days in the 30 days before consent — no. (%)</td><td class="xxxx-borders shading">135 (33.5)</td><td class="xxxx-borders shading">39 (35.8)</td><td class="xxxx-borders shading">96 (32.7)</td><td class="xxxx-borders shading">38 (33.3)</td><td class="xxxr-borders shading">36 (32.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Intensity of methamphetamine craving<a href="#core-t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">66.1±22.3</td><td class="xxxx-borders">65.7±22.2</td><td class="xxxx-borders">65.8±21.6</td><td class="xxxx-borders">66.7±21.3</td><td class="xxxr-borders">63.7±21.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Age of first methamphetamine use — yr</td><td class="xxxx-borders shading">24.8±9.9</td><td class="xxxx-borders shading">24.7±10.7</td><td class="xxxx-borders shading">24.8±9.6</td><td class="xxxx-borders shading">25.5±10.9</td><td class="xxxr-borders shading">24.8±9.1</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Other characteristics</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Coexisting cocaine use disorder according to DSM-5 criteria — no./total no. (%)</td><td class="xxxx-borders shading">31/365 (8.5)</td><td class="xxxx-borders shading">9/97 (9.3)</td><td class="xxxx-borders shading">22/268 (8.2)</td><td class="xxxx-borders shading">9/104 (8.7)</td><td class="xxxr-borders shading">9/100 (9.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Coexisting opioid use disorder according to DSM-5 criteria — no./total no. (%)</td><td class="xxxx-borders">27/370 (7.3)</td><td class="xxxx-borders">7/93 (7.5)</td><td class="xxxx-borders">20/277 (7.2)</td><td class="xxxx-borders">7/109 (6.4)</td><td class="xxxr-borders">7/104 (6.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Coexisting alcohol use disorder according to DSM-5 criteria — no./total no. (%)</td><td class="xxxx-borders shading">94/293 (32.1)</td><td class="xxxx-borders shading">25/77 (32.5)</td><td class="xxxx-borders shading">69/216 (31.9)</td><td class="xxxx-borders shading">23/85 (27.1)</td><td class="xxxr-borders shading">27/75 (36.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Coexisting cannabis use disorder according to DSM-5 criteria — no./total no. (%)</td><td class="xxxx-borders">116/318 (36.5)</td><td class="xxxx-borders">29/89 (32.6)</td><td class="xxxx-borders">87/229 (38.0)</td><td class="xxxx-borders">33/86 (38.4)</td><td class="xxxr-borders">33/85 (38.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Daily nicotine cigarette use — no./total no. (%)</td><td class="xxxx-borders shading">238/337 (70.6)</td><td class="xxxx-borders shading">66/99 (66.7)</td><td class="xxxx-borders shading">172/238 (72.3)</td><td class="xxxx-borders shading">73/89 (82.0)</td><td class="xxxr-borders shading">56/89 (62.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Score on PHQ-9 depression scale<a href="#core-t1fn7" role="doc-noteref">**</a></td><td class="xxxx-borders">19.9±6.5</td><td class="xxxx-borders">19.4±6.5</td><td class="xxxx-borders">20.0±6.5</td><td class="xxxx-borders">20.1±6.9</td><td class="xxxr-borders">19.5±5.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Score on Treatment Effectiveness Assessment<a href="#core-t1fn8" role="doc-noteref">††</a></td><td class="xxxx-borders shading">18.3±7.2</td><td class="xxxx-borders shading">16.7±7.0</td><td class="xxxx-borders shading">18.6±7.3</td><td class="xxxx-borders shading">18.4±7.5</td><td class="xxxr-borders shading">19.2±7.1</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02" data-xml-align="left">HIV-positive status — no./total no. (%)</td><td class="xbxx-borders">90/356 (25.3)</td><td class="xbxx-borders">24/92 (26.1)</td><td class="xbxx-borders">66/264 (25.0)</td><td class="xbxx-borders">24/96 (25.0)</td><td class="xbxr-borders">33/105 (31.4)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">Plus–minus values are means ±SD. The intention-to-treat population included all participants who underwent randomization in stage 1 and the participants who underwent randomization again in stage 2. DSM-5 denotes <i>Diagnostic and Statistical Manual of Mental Disorders</i>, fifth edition, and GED General Educational Development diploma. Percentages may not total 100 because of rounding.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">The total number reflects all participants who underwent randomization in stage 1.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">Race and ethnic group were reported by the participants. The “other” category included American Indian or Alaska Native (6 participants), Asian (11 participants), Native Hawaiian or Pacific Islander (2 participants), other (20 participants), multiracial (16 participants), don’t know (10 participants), and declined to answer (3 participants).</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">The remaining participants were unemployed, disabled, or retired; were keeping house; were students; or had other status.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t1fn5" role="paragraph" data-to-manipulate="true">The number of days of methamphetamine use at baseline was assessed for the 30 days before informed consent. One participant had only 24 days of assessment. Eligibility required a minimum of 18 days of methamphetamine use at baseline.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t1fn6" role="paragraph" data-to-manipulate="true">Methamphetamine craving (the intensity of the worst craving over the previous week) was assessed at each screening or baseline visit on a visual analogue scale; ratings on the scale, which range from 0 to 100, were averaged to determine a baseline craving, with 0 indicating no craving at all and 100 indicating the most intense craving possible.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="core-t1fn7" role="paragraph" data-to-manipulate="true">Depressive symptoms were assessed weekly with the use of the Patient Health Questionnaire 9 (PHQ-9); scores range from 0 to 27, with higher scores indicating greater depressive symptoms.</div></div><div role="doc-footnote" data-has="label"><div class="label">††</div><div id="core-t1fn8" role="paragraph" data-to-manipulate="true">Life satisfaction was reported by the participants and was assessed with the use of the Treatment Effectiveness Assessment, which consists of four items; the scores for each item are summed, and total scores range from 4 to 40, with higher scores indicating greater satisfaction.</div></div></div></figcaption></a><figcaption><div class="caption">Baseline Characteristics of the Participants in the Intention-to-Treat Population.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2020214_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2020214_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2020214/asset/3cb5d0ad-9321-4fd3-8f65-db82847fb114/assets/images/large/nejmoa2020214_t2.jpg" height="1539" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Outcome</th><th class="txxx-borders" colspan="2"><span>Stage 1</span></th><th class="txxx-borders" colspan="2"><span>Stage 2</span></th><th class="txxr-borders" colspan="2"><span>Treatment Effect</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Naltrexone–Bupropion<br>(N=109)</th><th class="xxxx-borders">Placebo<br>(N=294)</th><th class="xxxx-borders">Naltrexone–Bupropion<br>(N=114)</th><th class="xxxx-borders">Placebo<br>(N=111)</th><th class="xxxx-borders">Weighted Difference</th><th class="xxxr-borders">95% CI</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Primary outcome — no. of participants (%)<a href="#core-t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">18 (16.5)</td><td class="xxxx-borders shading">10 (3.4)</td><td class="xxxx-borders shading">13 (11.4)</td><td class="xxxx-borders shading">2 (1.8)</td><td class="xxxx-borders shading">11.1±2.5</td><td class="xxxr-borders shading">—</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Secondary outcomes</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Methamphetamine-negative urine samples — %<a href="#core-t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">20.4±2.2</td><td class="xxxx-borders shading">12.3±1.6</td><td class="xxxx-borders shading">19.2±2.6</td><td class="xxxx-borders shading">13.4±1.5</td><td class="xxxx-borders shading">6.8±1.7</td><td class="xxxr-borders shading">3.5 to 10.1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Change in methamphetamine craving according to visual analogue scale<a href="#core-t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">−30.0±3.2</td><td class="xxxx-borders">−22.3±1.8</td><td class="xxxx-borders">−31.8±3.2</td><td class="xxxx-borders">−20.5±1.7</td><td class="xxxx-borders">−9.7±2.1</td><td class="xxxr-borders">−13.8 to −5.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Change in score on PHQ-9 depression scale<a href="#core-t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">−4.8±0.7</td><td class="xxxx-borders shading">−3.3±0.3</td><td class="xxxx-borders shading">−4.4±0.6</td><td class="xxxx-borders shading">−3.7±0.4</td><td class="xxxx-borders shading">−1.1±0.4</td><td class="xxxr-borders shading">−1.9 to −0.2</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Change in score on Treatment Effectiveness Assessment<a href="#core-t2fn4" role="doc-noteref">§</a><a href="#core-t2fn5" role="doc-noteref">¶</a></td><td class="xbxx-borders">6.5±1.5</td><td class="xbxx-borders">2.2±1.0</td><td class="xbxx-borders">6.2±1.5</td><td class="xbxx-borders">2.5±1.1</td><td class="xbxx-borders">4.0±0.9</td><td class="xbxr-borders">2.3 to 5.7</td></tr></tbody></table></div></a><figcaption><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2020214_t2.jpg"></a><div class="notes"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2020214_t2.jpg"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">Plus–minus values are means ±SE unless otherwise noted. The total number in stage 1 reflects the number of participants who underwent randomization. The total number in stage 2 reflects the number of participants in the placebo group who did not have a response in stage 1 and therefore underwent randomization again in stage 2. No clinical conclusions can be drawn from secondary outcomes because confidence intervals were not adjusted for multiple comparisons.</div></div></a><div role="doc-footnote" data-has="label"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2020214_t2.jpg"><div class="label">†</div></a><div id="core-t2fn2" role="paragraph" data-to-manipulate="true"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2020214_t2.jpg">The primary outcome was a response, defined as at least three methamphetamine-negative samples out of four obtained at the end of stage 1 or stage 2. The overall treatment effect was defined as the weighted average of the responses in the naltrexone–bupropion group minus the responses in the placebo group, reported in percentage points ±SE, determined with the use of a weight of 0.43 in stage 1 and a weight of 0.57 in stage 2. The formula for this calculation is provided in the statistical analysis plan, available with the </a><a href="#ap1">protocol</a> at NEJM.org. The Wald z-test statistic for the primary outcome was 4.530 (P&lt;0.001).</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t2fn3" role="paragraph" data-to-manipulate="true">The percentage of methamphetamine-negative urine samples per participant was calculated by dividing the number of methamphetamine-negative urine samples obtained per stage by 12 (the number of expected samples per stage). The treatment effect is the between-group difference in the weighted average of negative urine samples, reported as percentage points ±SE.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t2fn4" role="paragraph" data-to-manipulate="true">The changes in stage 1 reflect the change from baseline, and the changes in stage 2 reflect the change from the end of stage 1. The treatment effect is the between-group difference in the weighted average change in scores, reported as the difference in points ±SE.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t2fn5" role="paragraph" data-to-manipulate="true">Data were available for 306 participants in stage 1 (74 in the naltrexone–bupropion group and 232 in the placebo group) and for 196 in stage 2 (98 in the naltrexone–bupropion group and 98 in the placebo group).</div></div></div></figcaption><figcaption><div class="caption">Primary and Secondary Outcomes in the Intention-to-Treat Population.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2020214_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2020214_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2020214/asset/d8d09485-9ca3-48a2-a4d2-fc7c3ff9e079/assets/images/large/nejmoa2020214_t3.jpg" height="3306" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders" colspan="3"><span>Stage 1</span></th><th class="txxr-borders" colspan="3"><span>Stage 2</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Naltrexone–Bupropion<br>(N=109)</th><th class="xxxx-borders">Placebo<br>(N=294)</th><th class="xxxx-borders">P Value</th><th class="xxxx-borders">Naltrexone–Bupropion<br>(N=114)</th><th class="xxxx-borders">Placebo<br>(N=111)</th><th class="xxxr-borders">P Value</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Participants with at least one serious adverse event — no. (%)<a href="#core-t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">1 (0.9)</td><td class="xxxx-borders shading">4 (1.4)</td><td class="xxxx-borders shading">1.00</td><td class="xxxx-borders shading">3 (2.6)</td><td class="xxxx-borders shading">4 (3.6)</td><td class="xxxr-borders shading">0.72</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Total no. of serious adverse events<a href="#core-t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">1</td><td class="xxxx-borders">4</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">4</td><td class="xxxx-borders">4</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Any adverse event — no. (%)</td><td class="xxxx-borders shading">99 (90.8)</td><td class="xxxx-borders shading">245 (83.3)</td><td class="xxxx-borders shading">0.08</td><td class="xxxx-borders shading">88 (77.2)</td><td class="xxxx-borders shading">77 (69.4)</td><td class="xxxr-borders shading">0.23</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Adverse events — no. (%)<a href="#core-t3fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Gastrointestinal events</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Nausea</td><td class="xxxx-borders">41 (37.6)</td><td class="xxxx-borders">45 (15.3)</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxx-borders">32 (28.1)</td><td class="xxxx-borders">8 (7.2)</td><td class="xxxr-borders">&lt;0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Diarrhea</td><td class="xxxx-borders shading">7 (6.4)</td><td class="xxxx-borders shading">18 (6.1)</td><td class="xxxx-borders shading">1.00</td><td class="xxxx-borders shading">6 (5.3)</td><td class="xxxx-borders shading">5 (4.5)</td><td class="xxxr-borders shading">1.00</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Vomiting</td><td class="xxxx-borders">13 (11.9)</td><td class="xxxx-borders">6 (2.0)</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxx-borders">12 (10.5)</td><td class="xxxx-borders">3 (2.7)</td><td class="xxxr-borders">0.03</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Constipation</td><td class="xxxx-borders shading">10 (9.2)</td><td class="xxxx-borders shading">7 (2.4)</td><td class="xxxx-borders shading">0.005</td><td class="xxxx-borders shading">2 (1.8)</td><td class="xxxx-borders shading">3 (2.7)</td><td class="xxxr-borders shading">0.68</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Dry mouth</td><td class="xxxx-borders">9 (8.3)</td><td class="xxxx-borders">5 (1.7)</td><td class="xxxx-borders">0.003</td><td class="xxxx-borders">1 (0.9)</td><td class="xxxx-borders">2 (1.8)</td><td class="xxxr-borders">0.62</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Upper abdominal pain</td><td class="xxxx-borders shading">5 (4.6)</td><td class="xxxx-borders shading">1 (0.3)</td><td class="xxxx-borders shading">0.006</td><td class="xxxx-borders shading">6 (5.3)</td><td class="xxxx-borders shading">3 (2.7)</td><td class="xxxr-borders shading">0.50</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Abdominal discomfort</td><td class="xxxx-borders">4 (3.7)</td><td class="xxxx-borders">5 (1.7)</td><td class="xxxx-borders">0.26</td><td class="xxxx-borders">1 (0.9)</td><td class="xxxx-borders">2 (1.8)</td><td class="xxxr-borders">0.62</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Nervous system symptoms and disorders</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Headache</td><td class="xxxx-borders">13 (11.9)</td><td class="xxxx-borders">68 (23.1)</td><td class="xxxx-borders">0.01</td><td class="xxxx-borders">11 (9.6)</td><td class="xxxx-borders">6 (5.4)</td><td class="xxxr-borders">0.31</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Dizziness</td><td class="xxxx-borders shading">11 (10.1)</td><td class="xxxx-borders shading">8 (2.7)</td><td class="xxxx-borders shading">0.006</td><td class="xxxx-borders shading">7 (6.1)</td><td class="xxxx-borders shading">1 (0.9)</td><td class="xxxr-borders shading">0.07</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Somnolence</td><td class="xxxx-borders">3 (2.8)</td><td class="xxxx-borders">10 (3.4)</td><td class="xxxx-borders">1.00</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (0.9)</td><td class="xxxr-borders">0.49</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Tremor</td><td class="xxxx-borders shading">5 (4.6)</td><td class="xxxx-borders shading">1 (0.3)</td><td class="xxxx-borders shading">0.006</td><td class="xxxx-borders shading">3 (2.6)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0.25</td></tr><tr data-type="row"><td class="xxlx-borders hanging13">Psychiatric symptoms and disorders</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Irritability</td><td class="xxxx-borders shading">6 (5.5)</td><td class="xxxx-borders shading">19 (6.5)</td><td class="xxxx-borders shading">0.82</td><td class="xxxx-borders shading">5 (4.4)</td><td class="xxxx-borders shading">4 (3.6)</td><td class="xxxr-borders shading">1.00</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Anxiety</td><td class="xxxx-borders">10 (9.2)</td><td class="xxxx-borders">14 (4.8)</td><td class="xxxx-borders">0.10</td><td class="xxxx-borders">1 (0.9)</td><td class="xxxx-borders">1 (0.9)</td><td class="xxxr-borders">1.00</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Insomnia</td><td class="xxxx-borders shading">6 (5.5)</td><td class="xxxx-borders shading">12 (4.1)</td><td class="xxxx-borders shading">0.59</td><td class="xxxx-borders shading">3 (2.6)</td><td class="xxxx-borders shading">1 (0.9)</td><td class="xxxr-borders shading">0.62</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Libido decreased</td><td class="xxxx-borders">4 (3.7)</td><td class="xxxx-borders">5 (1.7)</td><td class="xxxx-borders">0.26</td><td class="xxxx-borders">1 (0.9)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1.00</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Lability affected</td><td class="xxxx-borders shading">4 (3.7)</td><td class="xxxx-borders shading">4 (1.4)</td><td class="xxxx-borders shading">0.22</td><td class="xxxx-borders shading">2 (1.8)</td><td class="xxxx-borders shading">1 (0.9)</td><td class="xxxr-borders shading">1.00</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Depression</td><td class="xxxx-borders">2 (1.8)</td><td class="xxxx-borders">6 (2.0)</td><td class="xxxx-borders">1.00</td><td class="xxxx-borders">4 (3.5)</td><td class="xxxx-borders">4 (3.6)</td><td class="xxxr-borders">1.00</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">General disorders and injection-site reactions</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Fatigue</td><td class="xxxx-borders">8 (7.3)</td><td class="xxxx-borders">33 (11.2)</td><td class="xxxx-borders">0.35</td><td class="xxxx-borders">7 (6.1)</td><td class="xxxx-borders">8 (7.2)</td><td class="xxxr-borders">0.80</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Feeling jittery</td><td class="xxxx-borders shading">4 (3.7)</td><td class="xxxx-borders shading">2 (0.7)</td><td class="xxxx-borders shading">0.05</td><td class="xxxx-borders shading">1 (0.9)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1.00</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Malaise</td><td class="xxxx-borders">4 (3.7)</td><td class="xxxx-borders">1 (0.3)</td><td class="xxxx-borders">0.02</td><td class="xxxx-borders">1 (0.9)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1.00</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Metabolism and nutrition disorders</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Decreased appetite</td><td class="xxxx-borders">8 (7.3)</td><td class="xxxx-borders">6 (2.0)</td><td class="xxxx-borders">0.03</td><td class="xxxx-borders">3 (2.6)</td><td class="xxxx-borders">3 (2.7)</td><td class="xxxr-borders">1.00</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Musculoskeletal and connective tissue disorders</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Arthralgia</td><td class="xxxx-borders">4 (3.7)</td><td class="xxxx-borders">6 (2.0)</td><td class="xxxx-borders">0.47</td><td class="xxxx-borders">2 (1.8)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0.50</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Injury, poisoning, and procedural complications</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Contusion</td><td class="xxxx-borders">3 (2.8)</td><td class="xxxx-borders">5 (1.7)</td><td class="xxxx-borders">0.45</td><td class="xxxx-borders">0</td><td class="xxxx-borders">5 (4.5)</td><td class="xxxr-borders">0.03</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Skin and subcutaneous tissue disorders</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging23" data-xml-align="left">Hyperhidrosis</td><td class="xbxx-borders">8 (7.3)</td><td class="xbxx-borders">3 (1.0)</td><td class="xbxx-borders">0.002</td><td class="xbxx-borders">2 (1.8)</td><td class="xbxx-borders">0</td><td class="xbxr-borders">0.50</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">Events shown for stage 1 include events that occurred before the start of stage 2 in the safety population (all participants who underwent randomization). Events shown for stage 2 include those that occurred on or after the date of rerandomization in participants in the intention-to-treat population (participants who underwent randomization again in stage 2). Adverse events were classified according to the preferred term and system organ class of the <i>Medical Dictionary for Regulatory Activities</i>, version 22.1.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t3fn2" role="paragraph" data-to-manipulate="true">Of the 17 serious adverse events that occurred in the safety population (all participants who gave informed consent), 13 occurred in the intention-to-treat population and are reported in this table. Of the 13 serious adverse events, all except an event of seizure were recorded as serious because they resulted in either inpatient hospitalization or prolongation of an existing hospitalization. The additional 4 serious adverse events occurred after consent was given but before randomization; the events were hypertensive crisis (in 1 participant), genitourinary chlamydia infection (in 1 participant), neurosyphilis (in 1 participant), and appendicitis (in 1 participant). Four additional adverse events occurred in stage 2 in participants who did not undergo rerandomization (3 events in the naltrexone–bupropion group and 1 in the placebo group).</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t3fn3" role="paragraph" data-to-manipulate="true">The serious adverse events in stage 1 were substance-induced psychosis, paranoia, pancreatitis, and seizure (in 1 participant each) in the placebo group, and gastroenteritis in 1 participant in the naltrexone–bupropion group. The serious adverse events in stage 2 were gastroenteritis shigella, pneumonia, urosepsis, and being the victim of a crime (in 1 participant each) in the placebo group, and homicidal ideation, cellulitis, neck pain, and hyperglycemia (in 1 participant each) in the naltrexone–bupropion group.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t3fn4" role="paragraph" data-to-manipulate="true">The adverse events reported here are events of interest that occurred in 3% or more of participants in either stage in the naltrexone–bupropion group and events that had a P value of ≤0.05 for any pairwise comparison. Table S2 lists all adverse events that occurred during the trial in the safety population.</div></div></div></figcaption></a><figcaption><div class="caption">Adverse Events That Occurred during the Trial Period.<a href="#core-t3fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2020214_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2020214</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Hedegaard H, Bastian BA, Trinidad JP, Spencer MR, Warner M. Regional differences in the drugs most frequently involved in drug overdose deaths: United States, 2017. <em>Natl Vital Stat Rep</em> 2019;68:1-16.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32501207/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Regional+differences+in+the+drugs+most+frequently+involved+in+drug+overdose+deaths%3A+United+States%2C+2017&amp;publication_year=2019&amp;journal=Natl+Vital+Stat+Rep&amp;pages=1-16&amp;pmid=32501207" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Ellis MS, Kasper ZA, Cicero TJ. Twin epidemics: the surging rise of methamphetamine use in chronic opioid users. <em>Drug Alcohol Depend</em> 2018;193:14-20.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.drugalcdep.2018.08.029" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30326396/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000452578200003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Twin+epidemics%3A+the+surging+rise+of+methamphetamine+use+in+chronic+opioid+users.&amp;publication_year=2018&amp;journal=Drug+Alcohol+Depend&amp;pages=14-20&amp;doi=10.1016%2Fj.drugalcdep.2018.08.029&amp;pmid=30326396" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Ashok AH, Mizuno Y, Volkow ND, Howes OD. Association of stimulant use with dopaminergic alterations in users of cocaine, amphetamine, or methamphetamine: a systematic review and meta-analysis. <em>JAMA Psychiatry</em> 2017;74:511-519.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jamapsychiatry.2017.0135" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28297025/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000400464300015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Association+of+stimulant+use+with+dopaminergic+alterations+in+users+of+cocaine%2C+amphetamine%2C+or+methamphetamine%3A+a+systematic+review+and+meta-analysis.&amp;publication_year=2017&amp;journal=JAMA+Psychiatry&amp;pages=511-519&amp;doi=10.1001%2Fjamapsychiatry.2017.0135&amp;pmid=28297025" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Soares E, Pereira FC. Pharmacotherapeutic strategies for methamphetamine use disorder: mind the subgroups. <em>Expert Opin Pharmacother</em> 2019;20:2273-2293.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/14656566.2019.1681970" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31671001/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000493535700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pharmacotherapeutic+strategies+for+methamphetamine+use+disorder%3A+mind+the+subgroups.&amp;publication_year=2019&amp;journal=Expert+Opin+Pharmacother&amp;pages=2273-2293&amp;doi=10.1080%2F14656566.2019.1681970&amp;pmid=31671001" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Elkashef AM, Rawson RA, Anderson AL, et al. Bupropion for the treatment of methamphetamine dependence. <em>Neuropsychopharmacology</em> 2008;33:1162-1170.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/sj.npp.1301481" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17581531/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000253957600019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Bupropion+for+the+treatment+of+methamphetamine+dependence.&amp;publication_year=2008&amp;journal=Neuropsychopharmacology&amp;pages=1162-1170&amp;doi=10.1038%2Fsj.npp.1301481&amp;pmid=17581531" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Heinzerling KG, Swanson A-N, Hall TM, Yi Y, Wu Y, Shoptaw SJ. Randomized, placebo-controlled trial of bupropion in methamphetamine-dependent participants with less than daily methamphetamine use. <em>Addiction</em> 2014;109:1878-1886.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/add.12636" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24894963/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000343754500017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Randomized%2C+placebo-controlled+trial+of+bupropion+in+methamphetamine-dependent+participants+with+less+than+daily+methamphetamine+use.&amp;publication_year=2014&amp;journal=Addiction&amp;pages=1878-1886&amp;doi=10.1111%2Fadd.12636&amp;pmid=24894963" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Anderson AL, Li S-H, Markova D, et al. Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial. <em>Drug Alcohol Depend</em> 2015;150:170-174.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.drugalcdep.2015.01.036" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25818061/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000353600900023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Bupropion+for+the+treatment+of+methamphetamine+dependence+in+non-daily+users%3A+a+randomized%2C+double-blind%2C+placebo-controlled+trial.&amp;publication_year=2015&amp;journal=Drug+Alcohol+Depend&amp;pages=170-174&amp;doi=10.1016%2Fj.drugalcdep.2015.01.036&amp;pmid=25818061" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Runarsdottir V, Hansdottir I, Tyrfingsson T, et al. Extended-release injectable naltrexone (XR-NTX) with intensive psychosocial therapy for amphetamine-dependent persons seeking treatment: a placebo-controlled trial. <em>J Addict Med</em> 2017;11:197-204.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/ADM.0000000000000297" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28379861/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000402537100007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Extended-release+injectable+naltrexone+%28XR-NTX%29+with+intensive+psychosocial+therapy+for+amphetamine-dependent+persons+seeking+treatment%3A+a+placebo-controlled+trial.&amp;publication_year=2017&amp;journal=J+Addict+Med&amp;pages=197-204&amp;doi=10.1097%2FADM.0000000000000297&amp;pmid=28379861" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Jayaram-Lindström N, Hammarberg A, Beck O, Franck J. Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. <em>Am J Psychiatry</em> 2008;165:1442-1448.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1176/appi.ajp.2008.08020304" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18765480/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000260597000015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Naltrexone+for+the+treatment+of+amphetamine+dependence%3A+a+randomized%2C+placebo-controlled+trial.&amp;publication_year=2008&amp;journal=Am+J+Psychiatry&amp;pages=1442-1448&amp;doi=10.1176%2Fappi.ajp.2008.08020304&amp;pmid=18765480" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Ray LA, Bujarski S, Courtney KE, et al. The effects of naltrexone on subjective response to methamphetamine in a clinical sample: a double-blind, placebo-controlled laboratory study. <em>Neuropsychopharmacology</em> 2015;40:2347-2356.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/npp.2015.83" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25801501/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000359493700007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+effects+of+naltrexone+on+subjective+response+to+methamphetamine+in+a+clinical+sample%3A+a+double-blind%2C+placebo-controlled+laboratory+study.&amp;publication_year=2015&amp;journal=Neuropsychopharmacology&amp;pages=2347-2356&amp;doi=10.1038%2Fnpp.2015.83&amp;pmid=25801501" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and naltrexone </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of substances or cue-induced cravings. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Ballester J, Valentine G, Sofuoglu M. Pharmacological treatments for methamphetamine addiction: current status and future directions. <em>Expert Rev Clin Pharmacol</em> 2017;10:305-314.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27927042/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000396853100009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pharmacological+treatments+for+methamphetamine+addiction%3A+current+status+and+future+directions.&amp;publication_year=2017&amp;journal=Expert+Rev+Clin+Pharmacol&amp;pages=305-314&amp;pmid=27927042" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Chan B, Freeman M, Kondo K, et al. Pharmacotherapy for methamphetamine/amphetamine use disorder — a systematic review and meta-analysis. <em>Addiction</em> 2019;114:2122-2136.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/add.14755" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31328345/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000486258000001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pharmacotherapy+for+methamphetamine%2Famphetamine+use+disorder+%E2%80%94+a+systematic+review+and+meta-analysis.&amp;publication_year=2019&amp;journal=Addiction&amp;pages=2122-2136&amp;doi=10.1111%2Fadd.14755&amp;pmid=31328345" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Siefried KJ, Acheson LS, Lintzeris N, Ezard N. Pharmacological treatment of methamphetamine/amphetamine dependence: a systematic review. <em>CNS Drugs</em> 2020;34:337-365.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s40263-020-00711-x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32185696/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000520642500001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pharmacological+treatment+of+methamphetamine%2Famphetamine+dependence%3A+a+systematic+review.&amp;publication_year=2020&amp;journal=CNS+Drugs&amp;pages=337-365&amp;doi=10.1007%2Fs40263-020-00711-x&amp;pmid=32185696" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Banks ML, Smith DA, Blough BE. Methamphetamine-like discriminative stimulus effects of bupropion and its two hydroxy metabolites in male rhesus monkeys. <em>Behav Pharmacol</em> 2016;27:196-203.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/FBP.0000000000000224" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26886209/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000374892900014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Methamphetamine-like+discriminative+stimulus+effects+of+bupropion+and+its+two+hydroxy+metabolites+in+male+rhesus+monkeys.&amp;publication_year=2016&amp;journal=Behav+Pharmacol&amp;pages=196-203&amp;doi=10.1097%2FFBP.0000000000000224&amp;pmid=26886209" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Newton TF, Roache JD, De La Garza R II, et al. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. <em>Neuropsychopharmacology</em> 2006;31:1537-1544.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/sj.npp.1300979" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16319910/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000238418700019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Bupropion+reduces+methamphetamine-induced+subjective+effects+and+cue-induced+craving.&amp;publication_year=2006&amp;journal=Neuropsychopharmacology&amp;pages=1537-1544&amp;doi=10.1038%2Fsj.npp.1300979&amp;pmid=16319910" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Aboujaoude E, Salame WO. Naltrexone: a pan-addiction treatment? <em>CNS Drugs</em> 2016;30:719-733.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s40263-016-0373-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27401883/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000382155600005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Naltrexone%3A+a+pan-addiction+treatment%3F&amp;publication_year=2016&amp;journal=CNS+Drugs&amp;pages=719-733&amp;doi=10.1007%2Fs40263-016-0373-0&amp;pmid=27401883" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Hendershot CS, Wardell JD, Samokhvalov AV, Rehm J. Effects of naltrexone on alcohol self-administration and craving: meta-analysis of human laboratory studies. <em>Addict Biol</em> 2017;22:1515-1527.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/adb.12425" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27411969/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000413904600004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effects+of+naltrexone+on+alcohol+self-administration+and+craving%3A+meta-analysis+of+human+laboratory+studies.&amp;publication_year=2017&amp;journal=Addict+Biol&amp;pages=1515-1527&amp;doi=10.1111%2Fadb.12425&amp;pmid=27411969" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Roche DJO, Worley MJ, Courtney KE, et al. Naltrexone moderates the relationship between cue-induced craving and subjective response to methamphetamine in individuals with methamphetamine use disorder. <em>Psychopharmacology (Berl)</em> 2017;234:1997-2007.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s00213-017-4607-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28357460/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000403476500007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Naltrexone+moderates+the+relationship+between+cue-induced+craving+and+subjective+response+to+methamphetamine+in+individuals+with+methamphetamine+use+disorder.&amp;publication_year=2017&amp;journal=Psychopharmacology+%28Berl%29&amp;pages=1997-2007&amp;doi=10.1007%2Fs00213-017-4607-8&amp;pmid=28357460" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Mooney LJ, Hillhouse MP, Thomas C, et al. Utilizing a two-stage design to investigate the safety and potential efficacy of monthly naltrexone plus once-daily bupropion as a treatment for methamphetamine use disorder. <em>J Addict Med</em> 2016;10:236-243.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r19-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/ADM.0000000000000218" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27379819/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000380842500004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Utilizing+a+two-stage+design+to+investigate+the+safety+and+potential+efficacy+of+monthly+naltrexone+plus+once-daily+bupropion+as+a+treatment+for+methamphetamine+use+disorder.&amp;publication_year=2016&amp;journal=J+Addict+Med&amp;pages=236-243&amp;doi=10.1097%2FADM.0000000000000218&amp;pmid=27379819" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r19-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] of severe methamphetamine use disorder. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] on the basis of a small pilot study. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Fava M, Evins AE, Dorer DJ, Schoenfeld DA. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. <em>Psychother Psychosom</em> 2003;72:115-127.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r20-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1159/000069738" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/12707478/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000182854300002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+problem+of+the+placebo+response+in+clinical+trials+for+psychiatric+disorders%3A+culprits%2C+possible+remedies%2C+and+a+novel+study+design+approach.&amp;publication_year=2003&amp;journal=Psychother+Psychosom&amp;pages=115-127&amp;doi=10.1159%2F000069738&amp;pmid=12707478" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r20-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r21-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] a sequential parallel comparison design, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] sequential parallel comparison design. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Chen Y-F, Yang Y, Hung HMJ, Wang S-J. Evaluation of performance of some enrichment designs dealing with high placebo response in psychiatric clinical trials. <em>Contemp Clin Trials</em> 2011;32:592-604.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r21-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cct.2011.04.006" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21540126/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000292226500020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Evaluation+of+performance+of+some+enrichment+designs+dealing+with+high+placebo+response+in+psychiatric+clinical+trials.&amp;publication_year=2011&amp;journal=Contemp+Clin+Trials&amp;pages=592-604&amp;doi=10.1016%2Fj.cct.2011.04.006&amp;pmid=21540126" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r21-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r21-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] a sequential parallel comparison design, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] sequential parallel comparison design. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Tamura RN, Huang X. An examination of the efficiency of the sequential parallel design in psychiatric clinical trials. <em>Clin Trials</em> 2007;4:309-317.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r22-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1177/1740774507081217" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17848492/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000250185100002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=An+examination+of+the+efficiency+of+the+sequential+parallel+design+in+psychiatric+clinical+trials.&amp;publication_year=2007&amp;journal=Clin+Trials&amp;pages=309-317&amp;doi=10.1177%2F1740774507081217&amp;pmid=17848492" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r22-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r22-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] the full text of this article at NEJM.org). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] According to the sample-size calculation, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] use of a one-sided Wald z-test statistic </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">McHugh RK, Fitzmaurice GM, Carroll KM, et al. Assessing craving and its relationship to subsequent prescription opioid use among treatment-seeking prescription opioid dependent patients. <em>Drug Alcohol Depend</em> 2014;145:121-126.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.drugalcdep.2014.10.002" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25454409/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000347512700011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Assessing+craving+and+its+relationship+to+subsequent+prescription+opioid+use+among+treatment-seeking+prescription+opioid+dependent+patients.&amp;publication_year=2014&amp;journal=Drug+Alcohol+Depend&amp;pages=121-126&amp;doi=10.1016%2Fj.drugalcdep.2014.10.002&amp;pmid=25454409" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. <em>J Gen Intern Med</em> 2001;16:606-613.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1046/j.1525-1497.2001.016009606.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11556941/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000171184700005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+PHQ-9%3A+validity+of+a+brief+depression+severity+measure.&amp;publication_year=2001&amp;journal=J+Gen+Intern+Med&amp;pages=606-613&amp;doi=10.1046%2Fj.1525-1497.2001.016009606.x&amp;pmid=11556941" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Ling W, Farabee D, Liepa D, Wu L-T. The Treatment Effectiveness Assessment (TEA): an efficient, patient-centered instrument for evaluating progress in recovery from addiction. <em>Subst Abuse Rehabil</em> 2012;3:129-136.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2147/SAR.S38902" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23580868/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+Treatment+Effectiveness+Assessment+%28TEA%29%3A+an+efficient%2C+patient-centered+instrument+for+evaluating+progress+in+recovery+from+addiction.&amp;publication_year=2012&amp;journal=Subst+Abuse+Rehabil&amp;pages=129-136&amp;doi=10.2147%2FSAR.S38902&amp;pmid=23580868" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">Trivedi MH, Wisniewski SR, Morris DW, et al. Concise Associated Symptoms Tracking Scale: a brief self-report and clinician rating of symptoms associated with suicidality. <em>J Clin Psychiatry</em> 2011;72:765-774.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.4088/JCP.11m06840" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21733477/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000292340900005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Concise+Associated+Symptoms+Tracking+Scale%3A+a+brief+self-report+and+clinician+rating+of+symptoms+associated+with+suicidality.&amp;publication_year=2011&amp;journal=J+Clin+Psychiatry&amp;pages=765-774&amp;doi=10.4088%2FJCP.11m06840&amp;pmid=21733477" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="core-r27" class="citations"><div class="citation"><div class="citation-content">Doros G, Pencina M, Rybin D, Meisner A, Fava M. A repeated measures model for analysis of continuous outcomes in sequential parallel comparison design studies. <em>Stat Med</em> 2013;32:2767-2789.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/sim.5728" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23355369/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000320400900005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+repeated+measures+model+for+analysis+of+continuous+outcomes+in+sequential+parallel+comparison+design+studies.&amp;publication_year=2013&amp;journal=Stat+Med&amp;pages=2767-2789&amp;doi=10.1002%2Fsim.5728&amp;pmid=23355369" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="core-r28" class="citations"><div class="citation"><div class="citation-content">Courtney KE, Ray LA. Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology, and treatment literature. <em>Drug Alcohol Depend</em> 2014;143:11-21.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.drugalcdep.2014.08.003" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25176528/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000342871100002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Methamphetamine%3A+an+update+on+epidemiology%2C+pharmacology%2C+clinical+phenomenology%2C+and+treatment+literature.&amp;publication_year=2014&amp;journal=Drug+Alcohol+Depend&amp;pages=11-21&amp;doi=10.1016%2Fj.drugalcdep.2014.08.003&amp;pmid=25176528" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="core-r29" class="citations"><div class="citation"><div class="citation-content">Panenka WJ, Procyshyn RM, Lecomte T, et al. Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings. <em>Drug Alcohol Depend</em> 2013;129:167-179.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.drugalcdep.2012.11.016" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23273775/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000318754700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Methamphetamine+use%3A+a+comprehensive+review+of+molecular%2C+preclinical+and+clinical+findings.&amp;publication_year=2013&amp;journal=Drug+Alcohol+Depend&amp;pages=167-179&amp;doi=10.1016%2Fj.drugalcdep.2012.11.016&amp;pmid=23273775" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 10, 2025</div><div class="nejm-widget_item"><div><span> Lake Success, New York</span></div><div><span>Surgery, General</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/403253/wound-care-surgery-position-opening-northwell-health-/?query=fjwp&amp;rid=3059">Wound Care Surgery Position Opening, Northwell Health </a></div></div><div class="nejm-widget_item"><div><span> New York</span></div><div><span>Pediatrics, General</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/617205/seeking-child-abuse-pediatrician-ccmc/?query=fjwp&amp;rid=3059">Seeking Child Abuse Pediatrician, CCMC</a></div></div><div class="nejm-widget_item"><div><span> Texas</span></div><div><span>Internal Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/880289/physician-internal-medicine-hospitalist/?query=fjwf&amp;rid=385607">Physician - Internal Medicine Hospitalist</a></div></div><div class="nejm-widget_item"><div><span> Berkeley Heights, New Jersey</span></div><div><span>Radiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/861486/radiologist-breast-imager/?query=fjwf&amp;rid=12619">Radiologist - Breast Imager</a></div></div><div class="nejm-widget_item"><div><span> North Carolina</span></div><div><span>Pediatrics, General</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/883899/physician-ownership-1-hour-to-raleigh-nc-100-percent-outpatient-peds/?query=fjwf&amp;rid=5263">Physician Ownership | 1 hour to Raleigh, NC | 100% Outpatient Peds</a></div></div><div class="nejm-widget_item"><div><span> Florida</span></div><div><span>Surgery, Vascular</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/889646/vascular-surgeon-tampa-florida-hybrid-room/?query=fjwf&amp;rid=5263">Vascular Surgeon, Tampa Florida, Hybrid Room</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128720&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejmai%2Fregister%2Faifallpdf24%3Fpromo%3DOAFQF4NA%26query%3Dcm-rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Daifallpdf24&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2020214&amp;pubId=41289869&amp;placeholderId=101337&amp;productId=1007" target="_blank"><img src="/sda/128720/NEJ-AI-Fall24-300x250---002.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d665ab0632a444-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d665ab0632a444-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d665ab0632a444-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$037598630$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$037598630$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$037598630$--></div></div><div class="mlt-body"><!--?lit$037598630$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm-evidence" href="https://evidence.nejm.org/browse/nejm-article-type/review-article?query=recirc_Semantic" target="_self"><!--?lit$037598630$-->Review Article</a> <span class="mlt-article-site-label"><!--?lit$037598630$-->NEJM Evidence</span> <span class="mlt-article-pubdate"><!--?lit$037598630$-->Nov 28, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://evidence.nejm.org/doi/full/10.1056/EVIDra2300160?query=recirc_Semantic" target="_self">Methamphetamine Toxicities and Clinical Management</a></div><div class="mlt-article-authors"><!--?lit$037598630$-->P.O. Coffin and L.W. Suen</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$037598630$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$037598630$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$037598630$-->Aug 03, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2300184?query=recirc_Semantic" target="_self">Duration of Adjunctive Antidepressant Maintenance in Bipolar I Depression</a></div><div class="mlt-article-authors"><!--?lit$037598630$-->L.N. Yatham and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$037598630$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$037598630$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$037598630$-->Mar 23, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2204462?query=recirc_Semantic" target="_self">Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression</a></div><div class="mlt-article-authors"><!--?lit$037598630$-->E.J. Lenze and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/case-records-of-the-massachusetts-general-hospital" target="_self"><!--?lit$037598630$-->Case Records of the Massachusetts General Hospital</a> <span class="mlt-article-site-label"><!--?lit$037598630$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$037598630$-->May 08, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMcpc2412518?query=recirc_Semantic" target="_self">Case 13-2025: A 70-Year-Old Man with Weight Loss, Weakness, and Anorexia</a></div><div class="mlt-article-authors"><!--?lit$037598630$-->M.G. Gartland and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/clinical-practice" target="_self"><!--?lit$037598630$-->Clinical Practice</a> <span class="mlt-article-site-label"><!--?lit$037598630$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$037598630$-->Feb 15, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMcp2305428?query=recirc_Semantic" target="_self">Treatment-Resistant Depression in Older Adults</a></div><div class="mlt-article-authors"><!--?lit$037598630$-->D.C. Steffens</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2020214?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2020214" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2020214.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2020214"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Bupropion and Naltrexone in Methamphetamine Use Disorder</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2030186" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMra2028910" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Ewing’s Sarcoma</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2020214_f1.jpg"><img src="/cms/10.1056/NEJMoa2020214/asset/29a29702-674e-4ad1-b557-0e0c4d7ccae7/assets/images/large/nejmoa2020214_f1.jpg" height="3213" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Screening and Randomization.</div><div class="notes"><div role="doc-footnote">Participants may have had more than one reason for not undergoing randomization in stage 1. The analysis of the primary outcome was performed in the intention-to-treat population, which included all participants who underwent randomization in stage 1 and all participants who underwent randomization again in stage 2.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2020214_f2.jpg"><img src="/cms/10.1056/NEJMoa2020214/asset/15ab8cd1-de04-4fb7-812b-1b8ffc8b88d0/assets/images/large/nejmoa2020214_f2.jpg" height="2478" width="2640" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Responses and Methamphetamine-Negative Urine Samples.</div><div class="notes"><div role="doc-footnote">The primary outcome was a response, defined as at least three methamphetamine-negative urine samples out of a possible four obtained at the end of stage 1 (during weeks 5 through 6) or at the end of stage 2 (during weeks 11 through 12). We calculated the weighted average of the responses in each stage, and the difference between these results was used to determine the overall treatment effect. Panel A shows the percentage of participants with a response and the weighted average of the response in each trial group in the intention-to-treat population, which included all participants who underwent randomization in stage 1 and all participants who underwent randomization again in stage 2. Panel B shows the percentage of methamphetamine-negative urine samples according to stage and trial group in the intention-to-treat population. Placebo/naltrexone–bupropion refers to participants in the placebo group who did not have a response in stage 1 and were assigned to the naltrexone–bupropion group in stage 2. Placebo/placebo refers to participants in the placebo group who did not have a response in stage 1 and were assigned to the placebo group in stage 2. During the 12-week intervention period, participants visited the clinic twice per week, after which they had a visit at week 13 and week 16. The evaluation period was the last 2 weeks of each stage (each evaluation stage is shown in the shaded areas). The number of urine samples obtained indicates the number of urine drug screening results available according to trial group at each visit for all participants in the intention-to-treat population. Results of urine drug screenings obtained at the first visit during week 1 (the day of randomization) are not shown. Results of drug screenings obtained on or before the rerandomization date of each participant in stage 2 are not shown because these samples were obtained when participants were still receiving the regimen assigned in stage 1.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Baseline Characteristics of the Participants in the Intention-to-Treat Population.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Primary and Secondary Outcomes in the Intention-to-Treat Population.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Adverse Events That Occurred during the Trial Period.<a href="#fv-t3fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/384/2" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 384 No. 2</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jan 14, 2021</span></li><li data-toggle="tooltip" data-original-title="Visual Abstract" class="issue-item_meta-item"><span role="img" aria-label="Visual Abstract" tabindex="0" class="issue-item_visualAbstract"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-visual"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2030186" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">D.L. Bhatt and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jan 14, 2021</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2025797" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">J.R. Teerlink and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jan 14, 2021</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2030183" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">D.L. Bhatt and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2020214%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2020214&amp;pubId=41289869&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2020214%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2020214&amp;pubId=41289869&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id0996491405636293" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d665ab0632a444-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d665ab0632a444-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d665ab0632a444-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d665ab0632a444-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d665ab0632a444-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d665ab0632a444-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d665ab0632a444-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d665ab0632a444-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d665ab0632a444-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d665ab0632a444-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d665aaef2ba444',t:'MTc0OTUzMjU5Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d665aaef2ba444&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2020214?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=2-10"></script><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_jqhe012jyx62muca0lb3ci8yjyl1vvbqke00qdpm" data-transactionid="jqhe012jyx62muca0lb3ci8yjyl1vvbqke00qdpm" id="captureIFrame_jqhe012jyx62muca0lb3ci8yjyl1vvbqke00qdpm" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="jqhe012jyx62muca0lb3ci8yjyl1vvbqke00qdpm" target="captureIFrame_jqhe012jyx62muca0lb3ci8yjyl1vvbqke00qdpm" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_jqhe012jyx62muca0lb3ci8yjyl1vvbqke00qdpm" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_jqhe012jyx62muca0lb3ci8yjyl1vvbqke00qdpm" name="capture_screen"><input id="capture_signIn_js_version_jqhe012jyx62muca0lb3ci8yjyl1vvbqke00qdpm" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_jqhe012jyx62muca0lb3ci8yjyl1vvbqke00qdpm" name="js_version"><input id="capture_signIn_transactionId_jqhe012jyx62muca0lb3ci8yjyl1vvbqke00qdpm" data-capturefield="undefined" value="jqhe012jyx62muca0lb3ci8yjyl1vvbqke00qdpm" type="hidden" class="capture_transactionId_jqhe012jyx62muca0lb3ci8yjyl1vvbqke00qdpm" name="capture_transactionId"><input id="capture_signIn_form_jqhe012jyx62muca0lb3ci8yjyl1vvbqke00qdpm" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_jqhe012jyx62muca0lb3ci8yjyl1vvbqke00qdpm" name="form"><input id="capture_signIn_flow_jqhe012jyx62muca0lb3ci8yjyl1vvbqke00qdpm" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_jqhe012jyx62muca0lb3ci8yjyl1vvbqke00qdpm" name="flow"><input id="capture_signIn_client_id_jqhe012jyx62muca0lb3ci8yjyl1vvbqke00qdpm" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_jqhe012jyx62muca0lb3ci8yjyl1vvbqke00qdpm" name="client_id"><input id="capture_signIn_redirect_uri_jqhe012jyx62muca0lb3ci8yjyl1vvbqke00qdpm" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_jqhe012jyx62muca0lb3ci8yjyl1vvbqke00qdpm" name="redirect_uri"><input id="capture_signIn_response_type_jqhe012jyx62muca0lb3ci8yjyl1vvbqke00qdpm" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_jqhe012jyx62muca0lb3ci8yjyl1vvbqke00qdpm" name="response_type"><input id="capture_signIn_flow_version_jqhe012jyx62muca0lb3ci8yjyl1vvbqke00qdpm" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_jqhe012jyx62muca0lb3ci8yjyl1vvbqke00qdpm" name="flow_version"><input id="capture_signIn_settings_version_jqhe012jyx62muca0lb3ci8yjyl1vvbqke00qdpm" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_jqhe012jyx62muca0lb3ci8yjyl1vvbqke00qdpm" name="settings_version"><input id="capture_signIn_locale_jqhe012jyx62muca0lb3ci8yjyl1vvbqke00qdpm" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_jqhe012jyx62muca0lb3ci8yjyl1vvbqke00qdpm" name="locale"><input id="capture_signIn_recaptcha_version_jqhe012jyx62muca0lb3ci8yjyl1vvbqke00qdpm" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_jqhe012jyx62muca0lb3ci8yjyl1vvbqke00qdpm" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div><div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><yhe-djvywbwywzqg></yhe-djvywbwywzqg><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div></body></html>